Pharmacological and genetic modulation of the endocannabinoid system by Rüden, Eva-Lotta von
 
Pharmacological and genetic modulation  
of the endocannabinoid system: 
Evaluation of preventive strategies in the amygdala 
kindling model of temporal lobe epilepsy 
 
Dr. med. vet. Eva-Lotta von Rüden, 
née Schneider 
 
 
 
 
 
 
Dissertation of the 
Graduate School of Systemic Neurosciences 
der Ludwig-Maximilians-Universität München 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Submitted by Dr. med. vet. Eva-Lotta von Rüden, 
née Schneider 
from Hansestadt Lübeck, Germany 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
First reviewer/supervisor: Prof. Dr. Heidrun Potschka 
 
Second reviewer: Dr. Daniela Vogt-Weisenhorn 
 
 
 
 
 
 
 
Date of oral defense: 30.01.2015 

 
 
 
 
 
 
 
	  
 
 
 
 
 
 
 
 
To my family.
	  
Abstract  ix 
ABSTRACT 
Epilepsy is one of the most common chronic neurological diseases worldwide and the prevention of 
epileptogenesis is so far unmet. A major challenge in epilepsy research is the development of new 
therapeutic approaches for patients with therapy-resistant epilepsies, for epilepsy prevention and for 
disease modification. The endocannabinoid system serves as a retrograde negative feedback 
mechanism and one of its key functions is regulating neuronal activity within the central nervous 
system. Thus, the endocannabinoid system can be considered a putative target for central nervous 
system diseases including epilepsies.  
The purpose of this thesis was to evaluate the impact of the endocannabinoid and endovanilloid 
systems on both epileptogenesis and ictogenesis. Therefore, I modulated the systems 
pharmacologically and genetically and analyzed the impact on the generation of a hyperexcitable 
neuronal network as well as on ictogenesis in the kindling model of temporal lobe epilepsy. In 
addition, the impact of seizures on associated cellular alterations, like CB1-receptor (CB1R) 
expression and neurogenesis, was evaluated. 
I established that the endocannabinoid system affects seizure and afterdischarge duration dependent on 
the neuronal subpopulation being modulated. Genetic deletion of CB1Rs from GABAergic forebrain 
neurons caused shorter seizure duration. Deletion of CB1R from principal neurons of the forebrain and 
pharmacological antagonism with rimonabant (5 mg/kg) resulted in the opposite effect. Along with 
these findings, the CB1R density was increased in mice with recurrent induced seizures. However, 
neither genetic knockout nor pharmacological antagonism had any impact on the development of 
generalized seizures. In contrast to genetic deletion or pharmacological blockade of CB1Rs, 
modulation of transient receptor potential vanilloid receptor 1 (TRPV1) neither genetically nor 
pharmacologically with SB366791 (1 mg/kg) had an effect on the duration of behavioral or 
electrographic seizure activity. 
Pharmacological blockade of the 2-arachidonoylglycerol degrading enzyme, monoacylglycerol lipase 
(MAGL) with JZL184 (8 mg/kg), delayed the development of generalized seizures and decreased 
seizure and afterdischarge durations whereas in fully-kindled mice JZL184 (4, 8 and 16 mg/kg) had no 
relevant effects on associated seizure parameters. In addition, I confirmed by the use of conditional 
CB1R knockout mice that these effects are CB1R mediated.  
In conclusion, my findings support the concept that the endocannabinoid system may be a therapeutic 
target for decreasing seizure duration and that it is involved in terminating seizures as an endogenous 
mechanism. Moreover, targeting MAGL may be a promising strategy for an antiepileptogenic 
approach. Respective strategies are of particular interest for the management of long-lasting refractory 
status epilepticus and cluster seizures as well as for the prevention of the development of symptomatic 
epilepsies after an initial insult. 
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INTRODUCTION 
1. Epilepsy 
1.1. Definitions and classification 
The disease epilepsy is a multifactorial disorder associated with complex and various different brain 
pathologies, e.g., among others, tumors, infection, stroke or traumatic brain injury (Froscher and 
Neher 1994; Fisher et al. 2005). 
According to the working definition of the International League against Epilepsy (ILAE) and the 
International Bureau for Epilepsy (IBE), epilepsies are characterized by recurrent and unprovoked 
seizures, which have their origin in the central nervous system (Fisher et al. 2005; Fisher et al. 2014). 
The common clinical symptom is the epileptic seizure, which is based on the transient occurrence of 
abnormal, paroxysmal changes in the electrical neuronal activity of the brain (Fisher et al. 2005; 
Fisher et al. 2014). 
Approximately 50 million people suffer from epilepsy worldwide (World Health Organization 2006), 
whereof at least 40 million live in developing countries (World Health Organization 2006) and an 
estimated 6 million live in Europe (Cross 2011). Simply put, epilepsy is one of the most prevalent 
chronic neurological diseases. 
For a successful treatment regime, seizure characterization followed by a thorough diagnosis of the 
epileptic syndrome and the underlying cause is indispensable. The framework for an accurate 
diagnosis is provided by a classification system of the ILAE. The first proposal for seizure and 
epilepsy classification was made in 1960 and was updated in 1981 and 1989 (Dreifuss et al. 1981; 
Classification and Epilepsy 1989). Advances in neuroimaging, genomic technologies and new 
concepts in molecular biology have revealed that the classification concepts of 1981 and 1989 are 
outdated and have been refined recently. The approach presented in the 2010 ILAE Commission report 
represents a major step forward, but is still under revision (Berg et al. 2010; Berg and Millichap 2013). 
The concept for the classification of epilepsies and seizures is based on the mode and age of seizure 
onset, the underlying cause (etiology), EEG features as well as provoking or triggering factors (Berg et 
al. 2010). 
Etiologically, epilepsies are classified as symptomatic, idiopathic and cryptogenic epilepsies (Kwan 
and Brodie 2006). Since 2010, the ILAE recommends replacing this terminology with the following 
terms: structural or metabolic epilepsies, genetic epilepsies and epilepsies of unknown origin (Berg et 
al. 2010). Structural-metabolic (formerly “symptomatic”) epilepsies are caused by a structural or 
metabolic disorder of the brain. The underlying cause of genetic (formerly “idiopathic”) epilepsies is a 
genetic defect that contributes to epilepsy with seizures as the main symptom. If the cause is unknown 
and might be genetic, structural or metabolic the epilepsy is classified as unknown (formerly 
“cryptogenic”; Engel 2001; Berg et al. 2010). 
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Seizures are classified into generalized seizures and focal seizures. The generalized seizure originates 
at some place and rapidly spreads to the other hemisphere associated with loss of consciousness. 
Generalized seizures are further classified into tonic-clonic, absence, clonic, tonic, atonic, or 
myoclonic seizures (Berg et al. 2010). If the seizure activity continues over a long period without full 
recovery of the patient between single seizures, it is called status epilepticus (Fisher et al. 2005). 
In contrast, focal seizures are limited to one hemisphere and are accompanied either with or without 
loss of consciousness. Focal seizures may secondarily generalize and spread to the entire brain (Fisher 
et al. 2005). Figure 1 gives an overview of the clinical seizure classification. 
 
Figure 1. 
 
Overview of the clinical seizure classification (modified after Berg et al. (2010)). 
Until now, the main goal of epilepsy treatment has been to control the clinical symptoms and to reach 
seizure freedom by suppression of recurrent seizures. Usually, patients are treated with antiepileptic or 
anticonvulsant drugs (AEDs). The choice of medication should consider several factors, like the 
AED’s mechanism of action, drug interactions, the side-effect profile, and should include the epilepsy 
classification concept. The first choice should be an AED that is expected to be well-tolerated with 
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few side effects. Classical side effects caused by AEDs are dizziness, imbalance, nausea, and diplopia. 
Although the new AEDs have minimal side effects and have only a small potential for drug 
interaction, little improvement in AED efficacy has been made since phenobarbital was launched in 
1912. In up to 25-30% of patients, epileptic seizures cannot be controlled by AED treatment. These 
patients are considered to be drug resistant (Kwan and Brodie 2006). Moreover, cure cannot be 
achieved with AEDs used in clinical practice (Loscher 2002b). In addition, pharmacological treatment 
does not prevent the development or progression of epilepsy (Loscher and Brandt 2010). Surgical 
resection of the epileptic focus is an alternative treatment strategy but is rather applied to patients with 
drug resistant epilepsy or to patients with severe side effects due to AED treatment.	  
Among the epilepsy syndrome, temporal lobe epilepsy (TLE) is the most common form and is 
frequently very difficult to treat (Engel et al. 1998). TLE is considered to belong to the group of 
structural-metabolic epilepsies, although there are known forms of TLE with an underlying genetic 
cause (Berkovic et al. 1996; Vadlamudi et al. 2003; Salzmann and Malafosse 2012). Typically, TLE is 
an acquired epilepsy syndrome in which seizures originate in the temporal lobe triggered by a 
precipitating factor, such as traumatic brain injury, febrile seizure, stroke, encephalitis, perinatal 
hypoxia, or even a tumor. The precipitating factor is called the initial insult (Stefan et al. 2006). The 
initial insult initiates pathophysiological alterations in the hippocampus and parahippocampal regions 
leading to the formation of a proconvulsant neural network and finally to chronic epilepsy. This 
process is called epileptogenesis and is described below in more detail. 
1.2. Epileptogenesis and seizure-associated alterations 
Epileptogenesis is a dynamic process and is associated with the development of acquired epilepsies. 
Multiple pathophysiological alterations at the molecular, cellular and circuit level lead towards an 
imbalance of neuronal inhibition and excitation and to the manifestation of chronic epilepsy (Ziburkus 
et al. 2006; Ziburkus et al. 2013). However, the exact pathophysiology underlying the development of 
TLE remains still unknown. 
Classically, epileptogenesis is a three-step process: first, the initial insult; second, the latent or silent 
period; and third, chronic epilepsy with spontaneous and recurrent seizures. The concept of 
epileptogenesis is illustrated in figure 2. 
The initial insult, e.g., traumatic brain injury, febrile seizure, stroke, encephalitis, perinatal hypoxia, or 
a tumor, is the trigger, which sets the pathophysiological process of epileptogenesis in motion. 
The latent or silent period is defined as the time from a brain insult to the first clinical seizure 
(Pitkanen and Lukasiuk 2011). In this period no clinical seizures occur. However, data from animal 
experiments declare that non-convulsive electroencephalographic seizures occur before the first visible 
convulsive seizure (Bertram and Cornett 1993; Bertram and Cornett 1994; Williams et al. 2009). 
These studies point towards the possibility that in humans subclinical unrecognized seizures may 
predate the first clinical event. In humans the asymptotic period can range from a few weeks to some 
years (Annegers et al. 1998; Tsai et al. 2009). 
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Figure 2. 
Epileptogenesis of TLE and therapeutic intervention points. The stepwise process of epileptogenesis 
includes the initial insult, the latency period and the occurrence of recurrent seizures often associated 
with progression leading to pharmacoresistant epilepsy. The overall treatment goal is cure with the 
reversal of the pathophysiological alterations. The light blue arrows indicate possible therapeutic 
intervention points (modified from Löscher et al. (2008) and Pitkänen and Lukasiuk (2011)). 
During the latent period, molecular signaling pathways convert, e.g., immediate-early gene expression 
and the expression of ion channel and neurotransmitter receptors occur (Loscher et al. 2008; Pitkanen 
and Lukasiuk 2011). Furthermore, altered circuit-level mechanisms, like synaptic reorganization, 
dendritic plasticity, axonal sprouting and subsequently the formation of new excitatory synaptic 
connections (the so-called mossy fiber sprouting), are described (Babb et al. 1991; Peng et al. 2013; 
Singh et al. 2013). In addition, changes on the cellular level, e.g. neurodegeneration and neurogenesis, 
are hallmarks of epileptogenesis (Parent et al. 1997; Sutula et al. 2003; Pekcec and Potschka 2007; 
Scharfman and Gray 2007; Licko et al. 2013). Neuronal death, especially of GABAergic interneurons, 
consequently results in decreased GABA inhibition (Toth et al. 2010; Huusko et al. 2013). On the 
other hand, dentate gyrus mossy cells die as well (Danzer et al. 2010; Zellinger et al. 2011a). This 
causes reactive gliosis along with cell dispersion and generation of new dentate granule cells in ectopic 
locations (Scharfman et al. 2000; Scharfman et al. 2003; Cameron et al. 2011). All this is accompanied 
by inflammatory processes (Vezzani et al. 2011) and damage of the blood-brain-barrier (Tomkins et 
al. 2007; van Vliet et al. 2007). Some of these changes may be compensatory and reparative, but 
others are actively involved in the pathogenesis of epilepsy. Some alterations may contribute to the 
latent period and also continue beyond the diagnosis of epilepsy, and are further involved in the 
progressive nature of some epilepsies like TLE (Pitkanen and Lukasiuk 2009). 
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The prevention of epileptogenesis is still an unmet challenge. This raises the question of when the 
right time point for therapeutic intervention is and which are the best targets to aim for. Figure 2 
summarizes possible intervention points during epileptogenesis. 
The diversity of pathophysiological alterations during epileptogenesis suggests that the whole process 
is multifactorial and that the targets can vary over time. Relevant intervention time points of 
antiepileptogenesis are not only the prevention or delay of epilepsy, but also strategies to modify 
seizure frequency and seizure severity. Moreover, because epilepsy can be associated with psychiatric 
comorbidities, e.g., memory impairment or anxiety disorders (see chapter 1.3.), comorbidity 
modification should also be taken into account. Considering the complex pathophysiology of epilepsy, 
polytherapy might be more successful than monotherapy.  
1.3. Epilepsy-associated psychiatric comorbidities 
Many people suffering from epilepsy do not only have to cope with the disease itself, but also with co-
morbidities that tremendously affect their daily activities and quality of life. A comorbidity is defined 
as “a condition that occurs in association with another (i.e., epilepsy) at frequencies that are 
significantly greater than those observed in the appropriate control group” (Brooks-Kayal et al. 
2013). The comorbidity may be a cause of epilepsy, a consequence or even a separate condition. 
Among others, cognitive impairment, depression, anxiety disorders, attention deficit, autism, 
suicidality, psychosis and migraine can be associated with epilepsy. Very often, epilepsy associated 
with mood disorders is accompanied by poor seizure control and drug resistance (Hesdorffer et al. 
2006). For example, TLE is both the most common form of drug-resistant epilepsy and also the most 
common form associated with comorbidities, such as depression and cognitive impairments (Kanner 
2006a; Hoppe et al. 2007). Evidence suggests that the structural damage, like pyramidal cell loss in 
CA1 and CA3, gliosis, axonal sprouting and aberrant migration of granule cells in the hippocampus, is 
progressive (Yilmazer-Hanke et al. 2000). These changes in hippocampal neuronal networks may 
explain the progressive cognitive impairments and problems in memory consolidation (Hermann et al. 
2006). This may explain why an estimated large number of children (25-40 %) with epilepsy have 
impaired intellectual function and poor educational outcomes (Berg et al. 2004; Sogawa et al. 2010). 
In addition, there is growing evidence from animal models that epilepsy and behavioral abnormalities 
may share the same mechanisms of underlying neuropathology (Groticke et al. 2007, 2008; Takechi et 
al. 2011; Yutsudo et al. 2013). Serotonin receptor dysfunction, for example, is discussed as one of the 
main pathological mechanisms of depression (Yang et al. 2012). The same system may also be 
involved in lowering seizure thresholds of epilepsy patients (Choi et al. 2010; Gholipour et al. 2010). 
Since defects in the serotonin system are linked to both conditions, this could be an obvious 
explanation for a shared pathology of depression and epilepsy (Jobe 2003; Jobe and Browning 2005; 
Kanner 2006b). Combined animal models of the diseases may offer helpful tools to find possible 
targets for new treatment strategies in the complex relationship between epileptogenesis, 
neurodegeneration and behavioral and cognitive disturbances. 
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1.4. Antiepileptogenic and disease-modifying strategies 
The defining hallmark of epilepsy is recurrent spontaneous seizures. Unfortunately, the 
pathophysiological mechanisms leading to the hyperexcitable condition are poorly understood. 
Moreover, it is unlikely that only one central pathophysiologic mechanism underlies all different types 
of epilepsy. During the last decade research focused on different pharmacological strategies to modify 
pathophysiological molecular alterations with the overall goal of mitigating, preventing or even curing 
epilepsy. Molecular studies on neurodegeneration, neuronal plasticity and neurogenesis revealed that a 
combination of them contributes to the development of hyperexcitability and spontaneous seizures 
(Pitkanen and Lukasiuk 2011).  
One of the first ideas for antiepileptogenic strategies is the prolonged administration of conventional 
AEDs, e.g.,, diazepam, phenobarbital, phenytoin, valproate or carbamazepine after an initial insult has 
occurred. Many clinical trials and experimental studies have been carried out with the aim of 
preventing epilepsy, but none of them was successful (Temkin 2001; Loscher 2012). At least some 
AEDs, like carbamazepine, diazepam, levetiracetam, phenytoin, pregabalin, lacosamide or topiramate, 
mitigate neurodegeneration and over the long term they ease memory impairments (Capella and 
Lemos 2002; Andre et al. 2003; Frisch et al. 2007; Zhou et al. 2007; Cunha et al. 2009; Licko et al. 
2013). These studies indicate that prevention of neurodegeneration alone is not sufficient as an 
antiepileptogenic treatment strategy. 
Recently, neurotrophic factors, in particular brain-derived neurotrophic factor (BDNF) and fibroblast 
growth factor 2 (FGF-2), have been suggested to be promising candidates for the prevention of 
recurrent seizures. Many of the cellular mechanisms altered in epilepsy are regulated by neurotrophic 
factors in the healthy brain. Indeed, some research groups applied a combination of BDNF and FGF-2 
in different animal models and achieved reduced mossy fiber sprouting, neuroinflammation and less 
spontaneous seizures (Paradiso et al. 2009; Paradiso et al. 2011; Liu et al. 2013). On the contrary, 
others found that long lasting overexpression of BDNF instead promotes epileptogenesis (Heinrich et 
al. 2011). Nevertheless, the molecular mechanisms that control the synthesis of neurotrophic factors 
play a role in epilepsy and may be an attractive target for AED development. 
Another discussed strategy to prevent the progression of neurodegenerative conditions is the 
application of small molecules that resemble naturally occurring body peptides with protective 
potentials (Skaper 2008). These peptides lack unwanted side effects, e.g., bone marrow–stimulating 
properties of erythropoietin, but keep beneficial properties, e.g., neuroprotective, neurotrophic, and 
antiinflammatory properties. They are called mimetic peptides, because they resemble endogenous 
proteins. Over the past six years, our group was able to promote cell differentiation and 
neuroprotection and attenuate spatial learning deficits in epileptic animals by the administration of 
different mimetic peptides (Seeger et al. 2011; Zellinger et al. 2011a; Zellinger et al. 2011b; Russmann 
et al. 2013). Even if the number of animals exhibiting spontaneous recurrent seizures was not affected 
(Seeger et al. 2011), cellular and cognitive changes following SE are modified over the long term. 
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These results are encouraging and might suggest mimetic peptides as another molecular strategy with 
disease-modifying properties. 
Another reasonable strategy is to target inflammatory processes. In recent years, evidence has 
accumulated suggesting that the initial brain insult promotes inflammation, which is thought to be a 
trigger for the onset and progression of epilepsy (Vezzani et al. 2011). In vitro and in vivo findings 
suggest that proinflammatory cytokines like interleukin (IL)-1β, cyclooxygenase-2 and complement 
factors of the innate immune system are up-regulated at all three stages of epileptogenesis (Xiong et 
al. 2003; Balosso et al. 2008; Oliveira et al. 2008; Ravizza et al. 2008a). This prompted the hypothesis 
that “brain inflammation, in addition to its established contribution to ictogenesis, may play a role in 
the development of the epileptogenic process” (Vezzani et al. 2011). Indeed, modulatory strategies of 
the IL1-β system, e.g., by pharmacological inhibition of the Interleukin Converting Enzyme, blocked 
kindling acquisition and prevented seizures after a washout period (Ravizza et al. 2008b). Moreover, a 
combinatory approach of pharmacological inhibition of the Interleukin Converting Enzyme and the 
human recombinant IL1-β receptor antagonist in the post-Status-Epilepticus-model provides 
neuroprotection, but did not affect the onset of epilepsy, frequency and duration of seizures (Noe et al. 
2013). 
In summary, all strategies aim to modulate the molecular or cellular reorganization caused by the 
initial brain insult. So far, all efforts have been unsuccessful or at least did not lead to prevention or 
cure of epilepsy but only influenced the acute process of ictogenesis (Pitkanen 2002; Loscher and 
Brandt 2010). An expert group proposes that antiepileptogenesis treatment should completely prevent 
seizures (= ultimate goal), prolong the latent period (= partial prevention), or modify seizure 
frequency, duration and severity (= disease modification; Kobow et al. 2012). A combination of 
different strategies and a mixture of different drugs applied at different intervention time points may 
help to identify the optimum “drug-cocktail” and the time window of therapeutic intervention.  
1.5. Animal models of epileptogenesis 
Animal models of TLE are fundamental to the study of epileptogenesis. In general, an excellent 
animal model of a disease postulates three basic demands: constructive validity, face validity and 
predictive validity. Both the clinical symptoms (= face validity) and the pathogenesis (= constructive 
validity) in the model should resemble the human disease in many key aspects. Concerning the clinical 
efficacy of drugs in human medicine, animal models should allow the prediction of the therapeutic 
outcomes of future treatments (= predictive validity). A translational approach from bench to bedside 
can only be made with robust animal models. 
Epileptogenesis can be studied in many types of animal models (Figure 3). Basically, chronic animal 
models are distinguished from acute animal models. Chronic models are usually applied to study 
epileptogenesis whereas the acute seizure models are required for testing the anticonvulsant potency of 
newly developed antiepileptic drugs. 
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Figure 3. 
 
Schematic representation of chronic animal models in epilepsy research. Acute (seizure) models can 
be distinguished from chronic models. Chronic animal models are not only used to study epilepsy but 
also to study epileptogenesis. Chronic models are subdivided into models of structural-metabolic and 
genetic epilepsies. SE – status epilepticus; BLA – basolateral amygdala. 
To investigate the underlying mechanisms of epileptogenesis, animal models with either induced or 
spontaneously occurring seizures are available, including kindling, post-Status-epilepticus-models, 
traumatic brain injury and stroke models, models of febrile seizures, genetic rodent models of 
generalized epilepsy and even naturally occurring epilepsy in dogs (Pitkanen et al. 2007; Potschka 
2012; Potschka et al. 2013). In electrical and chemical animal models, seizures are triggered by 
electrical or chemical stimulation of the brain. In these models the seizures occur only associated with 
the stimuli. In contrast, in animal models with a strong initial electrical or chemical insult the animals 
develop spontaneous and recurrent seizures after a latency period. Both model types reflect the clinical 
situation of patients with symptomatic epilepsies.  
The animal model used in this study is the kindling model of TLE. The model is explained in more 
detail below.  
The kindling model of temporal lobe epilepsy 
Kindling is an animal model and seizures contribute to the progression of a hyperexcitable neuronal 
network. The generation of repeated, brief, focal seizures caused by electrical or chemical stimulation 
leads to permanently enhanced sensitivity to these stimuli with enhanced seizure duration and seizure 
severity, and ultimately to chronic epilepsy. 
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The kindling model was developed by Goddard and colleagues in 1967 and has been utilized in 
epilepsy research for almost fifty years (Goddard 1967). The verb “to kindle” literally means to 
enflame or to excite. This refers to repeated electrical stimulations inducing focal and later generalized 
seizures. These seizures promote or “kindle” the generation of a hyperexcitable neuronal network with 
long lasting cellular and molecular alterations. In the beginning of kindling only a small neural circuit 
is involved, visible as short focal seizures with eye blinking, facial clonus and chewing. Subsequently, 
additional circuits are recruited and the animals exhibit generalized seizures. After some stimulations 
seizure severity and seizure duration reach a plateau and the animal is supposed to be fully-kindled 
(McNamara 1984). This process of hyperexcitable neuronal network formation is compared to the 
process of epileptogenesis because the kindling model has many parallels with TLE in humans. 
Seizure duration increases and severity becomes more severe also in humans with recurrent seizures 
(Goddard et al. 1969; Racine 1972). Furthermore, EEG features in kindled mice resemble those in 
humans. High frequency spiking is followed by a progression to clonic bursts before a terminal 
suppression of the EEG appears (Bertram 2007). In addition, molecular and cellular alterations in the 
temporal lobe of kindled animals are comparable to the alterations in human TLE. Furthermore, 
kindling increases hippocampal neurogenesis (Parent et al. 1998; Scott et al. 1998) in correlation with 
seizure frequency (Jafari et al. 2012) and enhances synaptogenesis (Li et al. 2002). Moreover, in the 
kindling model neurodegeneration (von Bohlen und Halbach et al. 2004) and the generation of mossy 
fiber sprouting (Armitage et al. 1998), one of the hallmarks of TLE (Isokawa et al. 1993), was 
observed. These findings strongly support the idea of using the kindling model as a model to study 
epileptogenesis. However, the term “epileptogenesis” has to be used with great caution in this context. 
Epileptogenesis is defined as leading to recurrent and spontaneous seizures. In the kindling model only 
prolonged electrical stimulations over months may lead to spontaneous seizures (Pinel and Rovner 
1978; Michalakis et al. 1998; Sayin et al. 2003; Brandt et al. 2004). Spontaneous seizures in kindled 
animals have been difficult to replicate, thus questioning the model as an appropriate model for 
epileptogenesis. 
Nevertheless, repeated electrical stimuli with the sum of cellular and molecular alterations perfectly 
mimic the generation of a hyperexcitable neuronal network. Moreover, acute effects on seizure 
severity and duration can be easily examined in testing new pharmacological compounds. In addition, 
an excellent predictive validity for detecting clinically relevant treatment effects has been 
demonstrated (Loscher 2002a). Therefore, the kindling model was chosen to investigate the impact of 
the endocannabinoid and the endovanilloid systems on epileptogenesis and to test acute and chronic 
effects of cannabinoid type 1 receptor (CB1R) agonists and antagonists. 
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2. The endocannabinoid system 
2.1. Physiology of the endocannabinoid system 
For millennia humankind has known about psychoactive and medicinal effects of the marijuana plant 
(Russo 2007). In medieval Arabian medicine many of the currently known indications have already 
been described (Zuardi 2006). Lastly, after the chemical structure of Δ9-Tetrahydrocannabinol (THC) 
has been identified as the main active substance of the marijuana plant, detailed knowledge of the 
cannabinoid system and its effects could be obtained over the recent decades. Essentially, the 
endocannabinoid system consists of endogenous ligands (endocannabinoids) and cannabinoid 
receptors and enzymes, which coordinate endocannabinoid synthesis, release and degradation. 
In 1988 two different cannabinoid receptor types were identified in the rat brain (Devane et al. 1988): 
The cannabinoid receptor 1 (CB1R) and 2 (CB2R). The CB1R is localized in various tissues in the 
periphery and in the central nervous system, whereas the CB2R is almost exclusively expressed on 
immune cells and only to a limited extent in the central nervous system (Munro et al. 1993; Galiegue 
et al. 1995). The vast majority of the currently known effects of cannabinoids in the central nervous 
system are CB1R mediated and CB2R independent. Therefore, CB2Rs will not be covered any further 
here. 
The CB1R is a seven transmembrane G-protein coupled receptor, which is predominantly expressed 
on presynaptic termini of inhibitory as well as of excitatory synapses (Katona et al. 1999; Misner and 
Sullivan 1999). Among others, activation of the receptor and the metabotropic signal cascade inhibits 
the calcium influx by N- and P/Q- voltage gated calcium channels, the activity of adenylate cyclase 
and increases the open probability of different potassium channels (Twitchell et al. 1997; McAllister 
and Glass 2002). As a consequence of activation, cells, especially neurons, change their functional 
characteristics and neurotransmitter release is decreased (Freund et al. 2003).  
The hydrophobic properties of THC suggested that the endogenous ligand of the cannabinoid system 
must be a lipid molecule. In 1992, the arachidonic acid derivative arachidonylethanolamide 
(anandamide) was isolated from pig brains and identified as an endogenous ligand (Devane et al. 
1992). Anandamide (after ananda, the Sanskrit word for bliss) is synthesized from N-arachidonyl 
phosphatidyl ethanolamide by elimination of phosphorous acid. Three years later a second 
endocannabinoid, 2-Arachidonoylglycerol (2-AG), was discovered (Mechoulam et al. 1995). 2-AG is 
an arachidonic ester (Mechoulam et al. 1995), which arises from a different precursor molecule than 
anandamide. 
The synthesis of the endogenous ligands is initiated by presynaptic axonal depolarization, which 
causes an activity dependent Ca2+ influx (Di Marzo et al. 2004). Once the endocannabinoids are 
released into the synaptic cleft, they travel backwards to activate CB1Rs on presynaptic nerve 
terminals. To regulate the feedback loop, specific uptake transporters and degrading enzymes of 
neurons terminate the physiological effects of the ligands in the synaptic cleft (Beltramo et al. 1997; 
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Bisogno et al. 1997). 2-AG is hydrolyzed by monoacylglycerol lipase (MAGL) to arachidonic acid 
and glycerol (Dinh et al. 2002), whereas anandamide is degraded by the enzyme fatty acid 
amidhydrolase (FAAH) into arachidonic acid and ethanolamide (Cravatt et al. 1996; Hillard and 
Campbell 1997). Up to now, anandamide and 2-AG are the two most commonly studied 
endocannabinoids (Devane et al. 1992; Mechoulam et al. 1995; Sugiura et al. 1995; Di Marzo and De 
Petrocellis 2012).  
In simple terms, the endocannabinoid system is a retrograde feedback mechanism that is activated on 
demand. The overall effect of CB1R activation is a reduced inhibitory or excitatory neurotransmission. 
Figure 4 schematically summarizes the key features of the feedback loop.  
 
Figure 4. 
 
Schematic representation of the endocannabinoid system’s retrograde signaling. Neuronal 
depolarization causes neurotransmitter release (e.g., glutamate or GABA). Neurotransmitter receptors 
on the postsynaptic neuron are activated, leading to an increase of intracellular Ca2+-ions and 
induction of the on-demand endocannabinoid biosynthesis. Endocannabinoids like anandamide and 2-
AG diffuse across the synaptic cleft to presynaptic CB1R. Once activated, CB1Rs regulate ion 
channels to decrease neuronal activity. Termination of endocannabinoid activity is achieved by 
hydrolyzing enzymes. Anandamide is degraded by fatty acid amide hydrolase (FAAH) in the 
postsynaptic neuron, and 2-AG by monoacylglycerol lipase (MAGL) in the presynaptic neuron 
(modified from Ahn et al. (2008)). 
2.2. Genetic modulation of the endocannabinoid system 
Excessive glutamate release is the pathophysiological key factor leading to the generation of epileptic 
seizures (ictogenesis). Therefore, it is mandatory to understand the mechanisms of excitotoxic 
glutamate release and related neuronal circuits for the development of new therapeutic strategies. 
Given the fact that the endocannabinoid system strongly participates in neuroprotection (Abood et al. 
2001; Marsicano et al. 2003; Khaspekov et al. 2004) and that it regulates neurotransmitter release on 
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demand (Freund et al. 2003), it is crucial to identify in detail the neuronal subtypes, which are 
controlled by the endocannabinoid system. 
Genetic techniques are the most powerful tools to answer these questions. In this context gene 
targeting is a technique to investigate the function of a particular gene and its product (Thomas and 
Capecchi, 1987). However, this technique may also have some disadvantages: increased embryonic 
lethality and compensatory effects during development may preclude gene analysis in adult mice. In 
addition, pleiotropic effects in several organs and tissues may lead to a complex interpretation of the 
phenotype. For these circumstances the method of choice is to switch off a gene in a specific tissue at 
any given time, thus creating so called conditional knockout mice. Today the Cre / loxP technology is 
well-established. This technique allows the production of conditional somatic mutagenesis by the 
enzyme Cre-recombinase ("causes recombination", 38 kDa). This enzyme is originally synthesized by 
P1 bacteriophage (Austin et al. 1981). It efficiently catalyzes the intramolecular recombination of the 
loxP sites (meaning “locus of crossing over [x] of P1 recombinase”; 34 bp long). If both loxP sites are 
orientated in 5’ -3’ – direction in a cis-localization, the Cre enzyme catalyzes the cleavage and rejoins 
the DNA, thus excising the intervening piece of DNA. If the Cre enzyme is controlled by a specific 
promotor, it is cell- or tissue-specific expressed (Abremski and Gottesman 1981; Sternberg and 
Hamilton 1981; Sauer and Henderson 1988). Thus, the Cre / loxP technology enables researchers to 
study the tissue-specific function of a gene product.  
The generation of conditional knockout mice is a stepwise process. By gene targeting an essential part 
of the gene of interest is flanked with two Cre-recognition sequences, the loxP sites. Alleles like this 
are called floxed alleles (meaning “flanked by loxP sites”). If these floxed animals are also transgenic 
for a cell-specifically expressed Cre-recombinase, the gene of interest will be displayed and knocked 
out here (Tsien et al. 1996) but will preserve its function in every other cell or tissue. 
Gene targeting strategy for conditional CB1R knockout 
We used two different conditional CB1R knockout mouse lines generated by using the cre / loxP 
system (Marsicano et al. 2003; Monory et al. 2006). 
The conditional knockout mice were obtained using a stepwise breeding protocol. They were 
maintained on a predominant C57BL/6N background. The final breeding step (see Figure 4) was to 
cross CB1R floxed (CB1f/f) mice (Marsicano et al. 2003) with the respective Cre-expressing 
(CamKIIα-Cre and Dlx5/6-Cre) mouse line (Marsicano et al. 2003; Monory et al. 2006). 
For the first mouse line the regulatory sequence of the Cre enzyme is CamKIIα, a Ca2+/calmodulin-
dependent kinase IIα from a bacterial artificial chromosome (Casanova et al. 2001). The artificial as 
well as the natural regulatory sequence is highly expressed in the dentate gyrus, cornu ammonis, 
cortex, olfactory bulb and amygdala (Sola et al. 1999; Casanova et al. 2001). Lower levels of 
CamKIIα expression are detected in the striatum, the thalamus and the hypothalamus, whereas the 
expression is absent in the cerebellum and in the periphery (Sola et al. 1999; Casanova et al. 2001). 
Therefore, CB1f/f,CamKIIα littermates lack CB1R in all principal, mainly glutamatergic, neurons of the 
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forebrain, but not in adjacent interneurons, in the cerebellum and in the periphery. These mice show an 
increased level of fear adaption comparable to the behavior of total CB1R knockout mice (Kamprath 
et al. 2009). In addition, the corticosterone release is enhanced when animals are subjected to acute 
stress (Steiner et al. 2008). Moreover, these animals are more susceptible to seizures caused by 
chemical noxa (Marsicano et al. 2003; Monory et al. 2006). 
For the second mouse line the regulatory sequence of the Cre enzyme is the I56i and I56ii intergenic 
enhancer sequence of the zebrafish, which is very similar to the mouse’s Dlx5/Dlx6 genes (Zerucha et 
al. 2000). This gene region was transfected into a plasmid containing the Cre-coding gene sequence 
and the excised transgene was injected into fertilized eggs from mice (Zerucha et al. 2000) to gain 
Dlx5/6-Cre mice. These mice were further crossed with CB1f/f mice (see Figure 5). CB1f/f,Dlx5/6-Cre 
mice lack expression of CB1Rs in all GABAergic neurons of the forebrain (particularly in the 
hippocampal formation), but are rescued in pyramidal neurons (Monory et al. 2006). These animals 
show increased exploratory behavior in the basal state (Lafenetre et al. 2009), but otherwise the 
phenotype is not altered (Monory et al. 2006). 
Figure 5. 
 
Breeding protocol of the two conditional CB1R-knockout mouse lines. CB1f/f-mice were generated 
by Marsiciano et al. (2003) and crossed with the respective Cre mouse lines to obtain experimental 
animals and littermate controls (Marsicano et al. 2003; Monory et al. 2006). Experimental animals 
express the Cre enzyme either in principal neurons of the forebrain (promotor: open box; CamKIIα) 
or in GABAergic neurons of the forebrain (promotor: open boxes; i/ii (=Dlx5/6)), and therefore lack 
CB1Rs in specific neuronal subpopulations. P, parental generation; F1, Filial generation; open 
triangles, loxP sites; open box ‘CB1’, CB1 open reading frame; grey box ‘cre’, open reading frame 
Cre recombinase. 
2.3. Pharmacological modulators of the endocannabinoid system 
More than 40 years ago the most well-known cannabinoid Δ9-THC was isolated, synthesized and its 
psychoactive characteristics were demonstrated (Gaoni and Mechoulam 1964). Until now, a large 
number of cannabinoid analogues have been synthesized and characterized in animal models (Pertwee 
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2008, 2012; Starowicz and Di Marzo 2013). In 1991 the Sterling Research Group discovered a new 
class of aminoalkylindol analgesics acting as agonists at CB1R in the brain (Pacheco et al. 1991). The 
stereochemical structure of WIN55.212-2 has a high similarity to Δ9-THC, but the affinity and 
selectivity is higher for CB1R and CB2R (Pacheco et al. 1991; Compton et al. 1992). WIN55.212-2 is 
considered to be the prototype of the agonists, fulfilling the typical tetrad effect (analgesia, 
hypolocomotion, catalepsy and immobility) of cannabinoids. Today, a variety of chemical substances 
are available that affect endocannabinoid signaling either directly by interaction with the receptor 
(agonists and antagonists) or indirectly by modulating endocannabinoid levels and thus the receptor 
output (indirect agonists and indirect antagonists). Because of the high number of available chemical 
compounds, I will only focus on those agents used in this study. 
Rimonabant (SR141716A) 
SR141716A [N- (piperidin-1-yl)-5-(4-chlorophenyl)- 1-(2,4-dichlorophen- yl)-4-methyl-lH-pyrazole-
3-carboxamide hydrochloride] is a potent, competitive and selective CB1R antagonist with restricted 
activity to the central nervous system (Rinaldi-Carmona et al. 1994; Rinaldi-Carmona et al. 1995; 
Rinaldi-Carmona et al. 1996). Rimonabant was originally developed for the treatment of obesity (Pi-
Sunyer et al. 2006; Scheen et al. 2006) and was launched, approved for this indication, into the 
European market in 2006 under the brand name Accomplia®. Two years later, rimonabant was 
withdrawn from the European market due to an increased risk of psychiatric side effects, such as 
depression, insomnia, anxiety, and aggression (Moreira and Crippa 2009). In addition, case histories 
suggest a relationship with suicide (Topol et al. 2010). From a clinical perspective, the advantages and 
the restrictions of this drug have to be seriously interrogated. Nevertheless, for research purposes 
rimonabant is an excellent compound to study the endocannabinoid system and it is widely used as a 
tool to reverse cannabinoid induced effects. 
JZL184 
Termination of endocannabinoid signaling is strictly regulated by the endocannabinoid degrading 
enzymes FAAH and MAGL (Ahn et al. 2008). By inhibition of these enzymes, the concentration of 
anandamide and 2-AG is tremendously elevated causing the well-known cannabinoid behavioral 
effects normally mediated by direct acting agonists. Thus, the enzyme inhibitors act as “indirect-
agonists”. Decoupling of anandamide- and 2-AG-dependent signaling pathways by selective and 
specific pharmacological blockade of the respective degrading enzyme offers the possibility of directly 
addressing the tissue specific role of endocannabinoids in the brain. Accumulating evidence exists that 
MAGL is the primary enzyme responsible for the degradation of 2-AG (Dinh et al. 2002; Dinh et al. 
2004; Blankman et al. 2007). In 2009 Long and colleagues (2009) synthesized a potent and selective 
MAGL inhibitor that displays exceptional activity in vivo and is superior towards the existing enzyme 
inhibitors. The “old” and most well-described MAGL inhibitor URB602 is not potent enough for 
systemic administration in vivo (Mechoulam et al. 1995). The new compound was named after its 
inventor’s initials: JZL184 (Jonathan Z. Long). When administered to mice, JZL184 causes the classic 
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CB1R-dependent tetrad effect by an increase of brain 2-AG levels up to eight-fold (Long et al. 2009). 
Thereby, anandamide is not affected (Long et al. 2009). However, the development of tetrad effects, as 
well as pharmacological tolerance at higher dosages (40 mg/kg) and chronic administration 
(Schlosburg et al. 2010), may be a limitation for clinical use. In contrast, low dosage (~8 mg/kg) 
chronic treatment does not induce tolerance and does not alter memory consolidation (Busquets-
Garcia et al. 2011). These physical and chemical conditions highlight MAGL inhibition as a potential 
therapeutic target for epilepsy. 
2.4. The role of the endocannabinoid system in epilepsy 
The endocannabinoid system plays an important role in synaptic plasticity (Gerdeman and Lovinger 
2003; Chevaleyre et al. 2006; Marsicano and Lutz 2006) and mediates neuronal excitability 
(Marsicano et al. 2003). Moreover, the endocannabinoid system affects depolarization-induced 
suppression of excitation and inhibition (DSI and DSE, respectively) at neuronal synapses of several 
brain regions, including the hippocampus and the amygdala (Wilson and Nicoll 2002; Freund et al. 
2003; Zhu and Lovinger 2005; Hofmann et al. 2006). There are some neurological disorders, e.g., 
multiple sclerosis, post-traumatic stress disorder, traumatic brain injury, Parkinson’s disease and also 
epilepsy, in which the endocannabinoid system may ameliorate the course of the disease by auto-
protective up-regulation of endocannabinoid synthesis and release onto subpopulations of its receptors 
in certain locations (Pertwee 2005). Accordingly, the focus of research is on the therapeutic potential 
of agents acting on this system. Moreover, the history of cannabis for the treatment of various diseases 
reaches back about 5000 years (Russo 2007). Systematic research on the potential anticonvulsant 
potency of cannabinoids began in the early seventies. In 1973 and 1974 different groups started to 
investigate the anticonvulsant and antiepileptic potency of Δ9-THC in different epilepsy models, e.g., 
the audiogenic seizure model and the kindling and pentylenetetrazole model (Boggan et al. 1973; 
Corcoran et al. 1973; Wada et al. 1973; Chesher and Jackson 1974). Carlini and colleagues (1975) 
analyzed the non-psychoactive cannabinoid cannabidiol in the maximal-electroshock-model in mice 
and were able to show an anticonvulsant effect. In the recent years researchers pharmacologically 
addressed the role of the endocannabinoid system in the control of neuronal excitability and seizure 
thresholds in different animal models. Many lines of evidence suggest that the endocannabinoid 
system has an anticonvulsant potency and is critically involved in the suppression of seizure activity 
and termination (Marsicano et al. 2002; Marsicano et al. 2003; Naderi et al. 2008; Bhaskaran and 
Smith 2010a). In line with these findings, blocking CB1R activity by cannabinoid antagonists or 
genetic deletion is often proconvulsant (Marsicano et al. 2003; Monory et al. 2006; Kow et al. 2014). 
In our lab, the direct acting CB1R agonist WIN55.212-2 delayed the progression of seizure severity in 
the kindling model of TLE, but WIN55.212-2 and the FAAH inhibitor URB597 had only minor 
effects on seizure thresholds and seizure duration (Wendt et al. 2011). In addition, we revealed an 
impact on cell proliferation and neurogenesis, suggesting that activation of CB1Rs might also promote 
disease-modifying modalities (Wendt et al. 2011). In strong contrast to our findings, a study from 
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2009 claimed that the CB1R antagonist rimonabant, a seizure-enhancing drug, paradoxically prevents 
epileptogenesis when applied within a short time window following traumatic brain injury (Echegoyen 
et al. 2009). In summary, the main findings from in vitro cell culture studies and in vivo studies of 
epilepsy suggest that the endocannabinoid system has anticonvulsant properties under excitatory 
conditions but is often ineffective or even proconvulsant when inhibitory neurotransmission is 
blocked. Clearly, the particular importance is the net effect of the endocannabinoid system because the 
system is active on both excitatory and inhibitory neuronal subpopulations.  
Recently, the use of medical marijuana and one of its active ingredients, cannabidiol, is an intensively 
discussed topic among experts and patients with epilepsy. However, there is only limited knowledge 
about safety and efficacy of this semilegalized treatment option. In November 2013 the U.S. Food and 
Drug Administration granted an “Orphan Drug” status to the plant extract cannabidiol from GW 
Pharmaceuticals (Epidiolex®) for the treatment of Dravet Syndrome and in February 2014 for the 
treatment of Lennox-Gastaut Syndrome. In June 2014 the efficacy and safety data from 27 patients 
was published. The company reported an effective reduction of the seizure frequency up to seizure 
freedom and only mild or moderate side effects, like somnolence, fatigue, diarrhea, decreased appetite, 
and increased appetite. These first clinical data is very promising and gives first evidence for potential 
clinical benefit at least for a subgroup of patients with severe epilepsy. 
However, one of the major challenges is still to elucidate the anti- or proconvulsant mechanisms of the 
endocannabinoid system for the prevention and treatment of epilepsy. 
 
3. The endovanilloid system 
The transient receptor potential vanilloid type 1 channel (TRPV1; originally vanilloid receptor = VR1) 
is the main molecular transducer in sensorial systems. It is activated by various stimuli like heat 
(>42°C), low pH, voltage and the naturally occurring chemicals capsaicin, the active ingredient of red-
hot chili peppers, and resiniferatoxin (Szallasi and Blumberg 1990a; Holzer 1991; Caterina et al. 1997; 
Caterina 2007). Resiniferatoxin is a potent capsaicin analog. Autoradiographic studies with this 
radiolabeled ligand helped to identify TRPV1 (Szallasi and Blumberg 1990b), which was finally 
cloned in 1997 and characterized as a subtype of the Transient Receptor Potential family of non-
selective cation channels (Caterina et al. 1997). Unlike CB1R, TRPV1 is a six-transmembrane protein 
with a hydrophobic stretch between segment five and six (Figure 6; Caterina et al. 1997). Mezey and 
colleagues (2000) identified the existence of the receptor in the rat’s brain. Further studies confirmed a 
widespread distribution of TRPV1 in various brain areas, e.g., in the cortex, hippocampus and 
amygdala to name just a few (Toth et al. 2005; Cristino et al. 2006). When activated, TRPV1 is 
calcium-permeable and non-selective for cations, leading to increased neuronal excitability (van der 
Stelt et al. 2005). Next to the “classical” TRPV1 agonists, some endogenous arachidonic acid 
derivatives like anandamide functionally activate TRPV1, implying a dual role for endocannabinoids 
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(Al-Hayani et al. 2001; Kofalvi et al. 2007). However, stimulation of CB1Rs and TRPV1 causes 
opposing effects on intracellular calcium concentrations. As a consequence, excitatory and inhibitory 
neurotransmission is regulated in an opposing way. Anandamide suppresses GABAergic signaling via 
presynaptic CB1Rs (Kim and Alger 2010), but stimulates glutamate release via presynaptic TRPV1 
(Chavez et al. 2010; Grueter et al. 2010). TRPV1 may thereby also be involved in pathological 
conditions, like fear, anxiety, excitotoxcity and also epilepsy. Moreover, CB1Rs and TRPV1 are co-
expressed in several brain regions, e.g. hippocampus, basal ganglia, thalamus, hypothalamus, 
cerebellum and others (Cristino et al. 2006; Micale et al. 2009). This phenomenon suggests a cross 
talk between the two receptors and extends the effects caused by activation (Di Marzo and De 
Petrocellis 2012), thus leading to an even more complex situation. 
The role of the endovanilloid system in epilepsy 
Due to its physiological characteristics, TRPV1 is considered to play a role in epilepsy and 
epileptogenesis (Fu et al. 2009). Beyond this hypothesis, the first evidence exists from different in vivo 
models of epilepsy that TRPV1 may be implicated in the disease. In the majority of the studies 
pilocarpine or pentylenetetrazole-induced seizure models were used and TRPV1 was modulated 
pharmacologically by agonists or antagonists. Activation of TRPV1 accelerated epileptogenesis or 
increased epileptiform activity, whereas antagonism of TRPV1 led to retardation of epileptogenesis or 
suppression of epileptiform activity (Bhaskaran and Smith 2010b; Gonzalez-Reyes et al. 2013; Kong 
et al. 2014; Shirazi et al. 2014). In line with these findings is the study of Kong et al. (2014), who 
modified the endovanilloid system genetically. Deletion of TRPV1 increased hypothermic-induced 
seizure thresholds (Kong et al. 2014). Moreover, Manna and Umathe (2012) focused on the dual role 
of anandamide and confirmed an anticonvulsant effect in the low dosage range via TRPV1 and a 
proconvulsant effect in the high dosage range via CB1Rs in the pentylenetetrazole model. 
Paradoxically, there is also evidence that the TPRV1 agonist capsaicin prevents kainic acid induced 
seizures in mice (Lee et al. 2011). Furthermore, in human patients with TLE, Sun et al. (2013) 
demonstrated an up-regulation of TRPV1 in the cortex and in the hippocampus, further pointing 
towards a role of the endovanilloid system in epilepsy. However, the exact role of TRPV1 is still 
ambiguous. All experimental studies focused on the suppression of acute seizures, whereas chronic 
effects of TRPV1 modulation remain to be evaluated. 
To clarify the role of TRPV1 in epileptogenesis and ictogenesis, we combined genetic and 
pharmacological strategies and analyzed the impact on the generation of a hyperexcitable neuronal 
network in the kindling model of TLE. 
Genetic modulation of the endovanilloid system 
As mentioned above genetic techniques are a very powerful tool to analyze the function of a particular 
gene and its protein. Caterina et al. (2000) used these techniques and generated TRPV1 knockout mice 
as follows: A 10-kb HindIII subfragment was used to construct a target vector. The target vector 
contained the disrupted mouse TRPV1 gene: An exon, encoding a part of the fifth and all of the sixth 
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transmembrane domain, as well as the pore-loop region, was deleted. The target vector was inserted 
into JM1 embryonic stem cells by electropolarization. Surviving embryonic stem cells with verified 
homologues recombination at the VR1 locus were injected at the stage of a blastocyste into foster 
mothers. Male chimeras were mated with C57/Bl6 females and homozygote offsprings were further 
backcrossed for at least four generations with C57/Bl6 females to obtain a nearly isogenetic 
background. TRPV1 knockout mice showed a physiological response towards mechanical stimuli but 
TRPV1 mediated sensory pain was impaired. Moreover, anxiety-related behavior, conditioned fear 
and hippocampal long-term potentiation was disrupted in these mice (Marsch et al. 2007). 
Homocygotic offsprings along with corresponding littermate controls were used in all experiments. 
Pharmacological modulators of the endovanilloid system 
Some natural and some endogenous products have powerful pharmacological characteristics to either 
activate or block TRPV1 receptors. Figure 6 gives a schematic overview of the different binding sites 
at the TRPV1 receptor (Julius 2013). The endovanilloid binding site is located within the second and 
third transmembrane domain and at the pore-loop region (Jordt and Julius 2002). This binding site is 
sensitive to capsaicin, capsazepine (a synthetic antagonist) and resiniferatoxin (an agonist from 
Euphorbia cactus) as well as to endogenous factors like anandamide and other bioactive lipids that 
have a high structural similarity to capsaicin. These bioactive lipids are the so-called endovanilloids 
(Jordt and Julius 2002).  
Figure 6. 
 
Schematic structure-function map of TRPV1. The TRPV1 protein consists of six transmembrane 
domains and a pore-loop between domain five and six. The different TRPV1 domains confer sensitivity 
to different ligands. The endovanilloid binding site is located within the second and third 
transmembrane domain and at the intervening cytoplasmatic pore-loop. The proton binding site is 
indicated by the lemon and the spider toxin site is indicated by the spider. Furthermore, this schematic 
drawing gives information about regions being involved in channel modulation by cellular proteins 
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and second messengers like ATP. This figure is reproduced with permission from (Julius 2013). C, 
carboxy terminus; N, amino terminus; PLC, phospholiase C; PIP2, phosphatidylinositol-2-phasphate; 
PKC, proteinkinase C; PKA, proteinkinase A.  
Pharmaceutical companies invested time, expertise and money to design small, potent and selective 
molecules which block TRPV1 activity. They focused on the molecular structure of the TRPV1 
agonist capsaicin. Based on structure-activity relationships of the three capsaicin subregions (the 
aromatic ring-, amide bond- and hydrophobic side chain-regions), the classical TRPV1 antagonists 
have been identified. Some of them are listed in Table 1.  
Table 1. Classical TRPV1 antagonists 
Thiourea 
Analogs 
Urea Analogs Cinnamide Analogs 
Capsazepine A-425619 SB-366791 
JYL-1421 BCTC AMG-9810 
 JNJ-17203212  
 
The first TRPV1 antagonist, capsazepine, was identified by Walpole and colleagues in 1994 (Walpole 
et al. 1994). Capsazepine is a competitive TRPV1 antagonist. However, capsazepine has low 
metabolic stability and poor pharmacokinetic features (Vriens et al. 2009). Moreover, its selectivity for 
TRPV1 is restricted. Furthermore, capsazepine also inhibits acetylcholine receptors (Liu and Simon 
1997), voltage-gated Ca2+ channels (Docherty et al. 1997) and TRPM8 (Vadlamudi et al. 2003) and 
was, for these reasons, never considered for clinical use. 
As another strategy, pharmacological companies use large-scale, high-throughput screening of 
chemical libraries to identify chemically tractable TRPV1 antagonists. More recently, SB366791 was 
identified and characterized in vitro and in vivo as a highly selective and more potent TRPV1 
antagonist than capsazepine (Gunthorpe et al. 2004; Varga et al. 2005; Lappin et al. 2006). Due to its 
high selectivity and its good pharmacological features, we used SB366791 to block TRPV1 and to 
study the impact on the formation of a hyperexcitable epileptic network. 
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4. Aim and scope of thesis 
The overall aim of the current thesis is to determine whether pharmacological and genetic modulation 
of the endocannabinoid and endovanilloid systems may have preventive antiepileptogenic properties 
in the kindling mouse model of TLE. 
 
The specific aims of the two manuscripts are as follows: 
 
Research article 1: Analysis in conditional cannabinoid 1 receptor-knockout mice reveals neuronal 
subpopulation-specific effects on epileptogenesis in the kindling paradigm. 
 Evaluation if pharmacological antagonism at CB1R with rimonabant affects epileptogenesis 
and ictogenesis. 
 Evaluation if conditional CB1R knockout in principal neurons of the forebrain affects 
epileptogenesis and ictogenesis. 
 Evaluation if conditional CB1R knockout in principal neurons of the forebrain has an impact 
on seizure-associated neurogenesis. 
 Evaluation if conditional CB1R knockout in GABAergic neurons of the forebrain affects 
epileptogenesis and ictogenesis. 
 Evaluation if pharmacological antagonism at TRPV1 with SB366791 affects epileptogenesis 
and ictogenesis. 
 Evaluation if TRPV1 knockout affects epileptogenesis and ictogenesis. 
 
Research article 2: Inhibition of monoacylglycerol lipase - 2-arachidonoylglycerol mediates 
cannabinoid1-receptor dependent retardation of kindling progression in a mouse model of temporal 
lobe epilepsy. 
 Evaluation if pharmacological inhibition of the 2-AG degrading enzyme MAGL by JZL184 
has an antiepileptogenic and an anticonvulsant effect. 
 Investigation if any effects underlying the endocannabinoid signal cascade are CB1R 
mediated. 
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Abstract 
The endocannabinoid system serves as a retrograde negative feedback mechanism. It is thought to 
control neuronal activity in an epileptic neuronal network. The purpose of this study was to evaluate 
the impact of the endocannabinoid and endovanilloid systems on both epileptogenesis and ictogenesis. 
Therefore, we modulated the endocannabinoid and endovanilloid systems genetically and 
pharmacologically, and analyzed the subsequent impact on seizure progression in the kindling model 
of temporal lobe epilepsy in mice. In addition, the impact of seizures on associated cellular alterations 
was evaluated. 
Our principal results revealed that the endocannabinoid system affects seizure and afterdischarge 
duration dependent on the neuronal subpopulation being modulated. Genetic deletion of CB1-
receptors (CB1Rs) from principal neurons of the forebrain and pharmacological antagonism with 
rimonabant (5 mg/kg) caused longer seizure duration. Deletion of CB1R from GABAergic forebrain 
neurons resulted in the opposite effect. Along with these findings, the CB1R density was elevated in 
animals with repetitively induced seizures. However, neither genetic nor pharmacological 
interventions had any impact on the development of generalized seizures. 
Other than CB1, genetic deletion or pharmacological blockade with SB366791 (1 mg/kg) of transient 
receptor potential vanilloid receptor 1 (TRPV1) had no effect on the duration of behavioral or 
electrographic seizure activity in the kindling model. 
In conclusion, we demonstrate that endocannabinoid, but not endovanilloid, signaling affects 
termination of seizure activity, without influencing seizure severity over time. These effects are 
dependent on the neuronal subpopulation. Thus, the data argue that the endocannabinoid system plays 
an active role in seizure termination but does not regulate epileptogenesis. 
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Highlights: 
• CB1R deletion in principal neurons of the forebrain lowers seizure susceptibility 
• CB1R affects seizure duration dependent on neuronal subpopulation expression 
• The endocannabinoid system is an endogenous mechanism for seizure termination 
• TRPV1 do not play a role in the generation of a hyperexcitable network 
• The endovanilloid system is not involved in ictogenesis or seizure termination 
 
Keywords: 
seizure; hyperexcitable network; ictogenesis; CB1; TRPV1; endovanilloid; neurogenesis; GABA; 
glutamate; amygdala 
 
Abbreviations: 
CB1R- cannabinoid type 1 receptor 
TRPV1 - transient receptor potential vanilloid receptor 
SS – Seizure severity 
SD – Seizure duration 
ADD – Afterdischarge duration 
ADT – Afterdischarge threshold 
Cum ADD - cumulative afterdischarge duration 
DCX - doublecortin 
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Introduction 
Temporal lobe epilepsy is the most common type of epilepsy with focal seizure onset (Tellez-Zenteno 
and Hernandez-Ronquillo 2012). An initial brain-damaging insult can trigger a cascade of molecular 
and cellular alterations that form a hyperexcitable neuronal network and, eventually, the appearance of 
recurrent and spontaneous seizures (Pitkänen and Lukasiuk 2009). The generation of this 
hyperexcitable neuronal epileptic network is called epileptogenesis. In order to develop new 
prophylactic treatment strategies, it is essential to understand the mechanisms underlying 
epileptogenesis. 
The endocannabinoid system serves a central function as a key regulator of neuronal activity, synaptic 
transmission and neuronal plasticity in the central nervous system (Katona and Freund 2008). The 
presynaptically located cannabinoid type 1 receptors (CB1Rs) are G protein-coupled and widely 
expressed within the central nervous system (Piomelli 2003). When activated on demand by the 
binding of postsynaptically synthesized endocannabinoid ligands such as anandamide or 2-
arachidonoylglycerol, CB1R signaling attenuates both inhibitory neurotransmission and excitatory 
neurotransmission (Monory et al. 2006).  
The endocannabinoid anandamide can also activate transient receptor potential vanilloid (TRPV1, 
formerly vanilloid receptor VR1) channels (Smart et al. 2000). These channels are nonselective plasma 
membrane cation channels (Caterina et al. 1997). Stimulation of TRPV1 increases the release of 
glutamate in an activity-dependent manner (Peters et al. 2010). Thus, the duration of postsynaptic 
spiking is enhanced at glutamatergic synapses (Shoudai et al. 2010; Mori et al. 2012). It has been 
confirmed that TRPV1 not only modulate glutamatergic signaling not only in the rodent brain, but also 
in human cortical tissue (Mori et al. 2012). Therefore, targeting not only the endocannabinoid system 
but also the endovanilloid system may provide a promising strategy for the regulation of neuronal 
activity in epilepsies (Lutz 2004). 
Implying the cross-system functionality of endocannabinoids, target validation requires a 
comprehensive understanding of the complex neuromodulatory and protective properties of 
endocannabinoids against hyperexcitability and acute seizures (Marsicano et al. 2003; Hunt et al. 
2012).  
The detailed etiology of epileptogenesis remains unknown, and whether the endocannabinoid system 
is involved in epileptogenesis and promotes anti- or proconvulsant effects is still controversially 
discussed (Echegoyen et al. 2009; Dudek et al. 2010). This might be partly related to the dichotomous 
role of endocannabinoid signaling in different neuronal subpopulations. Conditional CB1R knockout 
mice with deletion in selected neuronal subpopulations offer an excellent opportunity to address the 
functional role of the endocannabinoid signaling cascade in glutamatergic vs. GABAergic forebrain 
neurons. Initial studies have already been performed in an acute chemical seizure model with systemic 
administration of kainate (Marsicano et al. 2003; Monory et al. 2006; Ruehle et al. 2013). The findings 
indicated that kainic acid-induced seizure severity is modulated by CB1-receptor expression on 
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cortical glutamatergic neurons. Recently, Kow and colleagues (2014) reported that genetic loss of 
CB1Rs plays a role in pilocarpine-induced seizures and seizure severity. However, none of the studies 
provide information about the impact of CB1Rs on seizure thresholds or on epileptogenesis. 
Considering CB1Rs as a putative target for anticonvulsant or antiepileptogenic interventions, 
respective information is urgently needed. In a previous study, we analyzed the impact of 
pharmacological CB1R agonism on kindling epileptogenesis. In this study we revealed that the direct 
CB1R agonist WIN55.212-2 delayed kindling acquisition whereas the indirect CB1R agonist URB597 
did not affect seizure progression in the kindling paradigm (Wendt et al. 2011). These findings again 
raise the question about the impact of different neuronal subpopulations. Thus, we aimed to 
thoroughly assess the consequences of conditional CB1R-knockout in direct comparison with 
pharmacological blockade of CB1R on epileptogenesis in the kindling paradigm.  
In view of the dual function of endocannabinoids as well as the suggested link between the 
endovanilloid system and epilepsy, there is only limited data from experiments with rather unspecific 
pharmacological tools available. Therefore, we aim to elucidate the effects of TRPV1 knockout as 
well as specific TRPV1 antagonism on epileptogenesis in the kindling paradigm. 
In the above-mentioned epilepsy model, seizure discharges caused by electrical stimulation of the 
amygdala via a chronically implanted electrode lead to a progressive and permanent increase in the 
behavioral and electrographic seizure response (Loscher and Brandt 2010). Thus, kindling assesses the 
impact of genetic and pharmacological modulation on seizure progression, which reflects the 
formation of a hyperexcitable network (McIntyre et al. 2002; Morimoto et al. 2004). In addition, one 
can precisely determine the impact on seizure thresholds before and following kindling acquisition 
based on application of systematically increasing stimulation intensities. 
The aim of this study was to evaluate whether targeting the endocannabinoid and endovanilloid 
systems might (1) affect epileptogenesis (2) have an impact on ictogenesis and (3) render a basis for 
disease-modifying approaches. 
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Materials and Methods 
Animals and electrode implantation 
Male NMRI mice were purchased at a body weight of 21-25 g (Harlan Netherlands, Horst, 
Netherlands). Male CB1f/f;CaMKIIαCre mice, (CamK-CB1 KO; (Marsicano et al. 2003)), CB1f/f,Dlx5/6-Cre 
mice (Dlx-CB1 KO; (Monory et al. 2006)), CB1R-null mutant mice CB1–/– (CB1–KO; (Marsicano et 
al. 2002)) as well as VR1-/- mice (Caterina et al. 2000) breeding pairs were obtained from The Jackson 
Laboratory, TRPV1-KO) and their respective wildtype littermate controls (CamK-CB1, Dlx-CB1, 
CB1- and TRPV1-WT) were bred at the Max-Planck Institute of Biochemistry (Martinsried, 
Germany) and transferred with a weight of 21-25g to our institute. CamK-CB1 KOs lack CB1Rs in 
principal forebrain neurons and Dlx-CB1 KOs in GABAergic forebrain neurons. CB1-KOs and 
TRPV1-KOs do not express the respective receptors at all. Mice were derived from heterozygous 
breeding pairs (TRPV1-KO and –WT) or from Cre-negative mothers and Cre-positive fathers (CamK-
CB1 and Dlx-CB1). CamK-CB1 KO, Dlx-CB1 KO, CB1-KO and TRPV1-KO were genotyped by 
PCR using a slightly modified protocol as described previously by (Caterina et al. 1997b; Caterina et 
al. 2000; Casanova et al. 2001; Marsicano et al. 2003; Monory et al. 2006). The animals were kept 
under controlled environmental conditions (24–25°C; humidity 50–60%; 12 h dark/light cycle, lights 
on from 7am – 7pm) with free access to water and standard laboratory food. Experimental procedures 
have been carried out in accordance with the EU directive 2010/63/EU for animal experiments, with 
the German Animal Welfare act and were approved by the responsible government (license numbers: 
55.2-1-54-2532-186-09 and 55.2-1-54-2532-93-11). 
To minimize the impact of circadian variations, all experiments were performed within the same time 
period (8 a.m. to 1 p.m.). 
A teflon-isolated bipolar stainless steel electrode with a diameter of 280µm was stereotactically 
implanted into the right amygdala as described previously (Jafari et al. 2012b). All animals received 
meloxicam injections (0.2 mg/kg, s.c., Metacam®, Boehringer Ingelheim, Ingelheim, Germany) 30 
min prior and 24 h after the surgery to guarantee analgesia. Chloralhydrate (400 mg/kg in 10 ml saline 
i.p., Merck KGaA, Darmstadt, Germany) in combination with bupivacaine 2% (5 ml/kg s.c., 
Jenapharm®,Mibe, GmbH, Brehna) was used for anesthesia. The stereotaxic coordinates in millimeter 
relative to bregma were AP -1.0, L +3.2, DV -5.3 for NMRI mice, AP -1.2, L +3.5, DV -5.2 for 
CamK-CB1 mice and AP -1.4, L +3.5, DV -5.0 for Dlx-CB1 and TRPV1 mice. Following surgery, all 
the animals were allowed to recover for at least two weeks. 
 
Kindling procedure 
The initial afterdischarge threshold was determined following a stepwise protocol as described 
previously (Pekcec et al. 2007). The animals were kindled via daily electrical stimulation (1 ms, 
monophasic square-wave pulses, 50 Hz for 1 s), five times per week, either with a stimulation current 
20% above the initial afterdischarge threshold (pharmacological modulation: rimonabant) or with 700 
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µA (all genetic modulations and pharmacological modulation: SB366791). In the pharmacological 
modulation with rimonabant the interindividual seizure thresholds varied. To exclude a bias, each 
mouse was stimulated with individual stimulation currents 20 % above the afterdischarge threshold. 
For all the other experiments suprathreshold stimulation with 700 µA was used. The stimulation 
current of 700 µA was chosen based on the range of the initial afterdischarge seizure thresholds. In 
previous experiments in our lab, using individualized stimulation strength (20 % above initial 
threshold) did not make a difference as compared to the suprathreshold stimulation with 700 µA, both, 
regarding the response to the first stimulation following threshold determination and regarding the 
kindling rate. The only difference was that kindling with 700 µA resulted in a more stable fully-
kindled state. The seizure severity was scored according to a slightly modified Racine scale (Racine 
1972): 1, immobility, eye closure, ear twitching, twitching of vibrissae, sniffing, facial clonus; 2, head 
nodding associated with more severe facial clonus; 3, clonus of one forelimb; 4 bilateral forelimb 
clonus with or without rearing; 5 bilateral fore- and hindlimb clonus and falling with or without 
rearing. Kindling stages one and two represent focal seizures (limbic seizures), while beginning with 
seizure stage three, the seizures start evolving into clonic seizures (stages 3-5), a process of secondary 
generalization. At stages four and five, seizures involve both hemispheres (bilateral clonus) and thus, 
they are generalized. Motor seizure duration was stopped using an electronic timer and is defined as 
the visually determined time period of generalized seizure activity plus subsequent focal seizure 
activity as total motor seizure duration. In addition, electrographic afterdischarge duration was 
recorded. The sum of afterdischarge durations throughout the experiment was calculated as the 
cumulative afterdischarge duration. 
As we were only interested in kindling progression rates, and did not aim for experiments in fully-
kindled mice, we did not continue stimulations once all control mice exhibited at least one generalized 
stage four or five seizure. Depending on the experiment and on the mouse strain, we had to adjust the 
‘standard’ kindling protocol. We know from several years of kindling experience that mice with 
different genetic backgrounds (here NMRI or C57/BL6) may kindle faster or slower. The kindling 
procedure was stopped, when all mice from the control group, either being vehicle-treated or littermate 
control, experienced at least one generalized stage four or five seizure. This definition has been 
applied to each single experiment, explaining the different numbers of stimulation. Thus, NMRI mice 
received 20 and CamK-CB1/Dlx-CB1/TRPV1-mice (bred on a C57/BL6 background) 10 electrical 
stimulations. In addition, we also made the experience that kindled mice do not reproducibly exhibit 
the highest seizure score (5) even if stimulations are continued for a long time. In contrast, rats reliably 
exhibit the highest seizure score once the kindled state is reached. Next, we determined the post-
kindling afterdischarge following the stepwise procedure (Pekcec et al. 2007). One Dlx-CB1 KO 
mouse was statistically identified as significant outlier and was excluded from all further analysis. One 
vehicle animal received erroneously the TRPV1 antagonist and was therefore excluded from following 
analysis. Electrode-implanted controls (NMRI vehicle, CamK-CB1/Dlx-CB1/TRPV1-KO/WT mice) 
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were exposed to identical daily handling procedures except from the electrical stimulation. 
For the pharmacological modulation with the TRPV1 antagonist a modified version of the above 
mentioned protocol was used: following determination of initial afterdischarge thresholds, the animals 
were grouped into vehicle-treated and TRPV1 antagonist-treated animals. We evaluated a second 
afterdischarge threshold 30 min after drug or vehicle application. These mice then received 15 daily 
electrical stimulations. 
Six to twelve animals formed an experimental group. 
 
Drugs: 
SR141716 and SB366791: 
The CB1R antagonist rimonabant (SR141716A – [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamidehydrochlo-ride] (CAS 158681-13-1, axon 
medchem BV, Groningen, The Netherlands)) and the TRPV1 antagonist SB366791 ([N-(3-
methoxyphenyl)-4-chlorocinnamide], CAS 472981-92-3, biomol GmbH, Hamburg, Germany) were 
dissolved in a solution of 99 % Ethanol, cremophor EL (Sigma-Aldrich, Taufkirchen, Germany) and 
saline (1:1:18). The dosages for rimonabant (5 mg/kg) and for SB366791 (1 mg/kg) as well as the pre-
treatment time of 30 min were based on previous studies (Micale et al. 2013). Both compounds were 
injected i.p. at a volume of 10 ml/kg bodyweight always 30 min prior to the kindling stimulation. 
Control experiments with administration of a vehicle solution (99 % Ethanol, cremophor EL, saline; 
1:1:18) were performed in parallel. 
 
BrdU 
Dividing cells can be labeled by administration of DNA precursors like the thymidine analogue 
bromodeoxyuridine (BrdU), which is incorporated into the DNA during the S-phase of the cell cycle. 
BrdU is available for about 30 min after injection, and thus labels any cells proliferating during this 
period (Packard et al. 1973). We injected all mice (Kindled and control animals) with BrdU (50 mg/kg 
i.p.; Sigma-Aldrich, Hamburg, Germany) three times a week, once directly following the kindling 
stimulation and again in the afternoon (NMRI: total injections: 26; CB1, GABA, and TRPV1 mice: 
total injections: 14). BrdU administrations did not influence the state or the performance of the 
animals following seizure activity. 
 
Tissue preparation and immunostaining 
The anxiety- and locomotor-associated behavior of all animals was evaluated in the light-dark box and 
the open field on consecutive days subsequent to kindling experiments. However, we did not intensify 
the behavioral analysis, because neither kindling nor pharmacological or genetic modulation of both 
systems exerted any consistent and reproducible behavioral effects.  
At a maximum of six days after the last seizure, the mice were deeply anesthetized with pentobarbital 
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(narcoren® 400 mg/kg i.p., Merial GmbH, Halbergmoos, Germany) and transcardially perfused with 
4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The brains were removed and transferred 
into 30 % sucrose on the following day. The brains were stored at 4 °C until they were cut into coronal 
sections, 40 µm thick, collected in five series, on a microtome (Frigomobil, Reichert-Jung; 
Heidelberg-Nußloch, Deutschland). For long-term storage at -80 °C, we transferred the sections into a 
cryoprotectant solution (glycerol and 0.1 M phosphate buffer, pH 7.4, 1:1 in volume). 
One of the series was stained with thionin for verification of the electrode localization. 
For CB1R immunostaining, free-floating sections were washed, pre-incubated in 1.5 % BSA, and then 
treated for two days at 4 °C with a polyclonal rabbit anti-CB1 antibody (1:500; ABCAM, Cambridge, 
UK), which recognizes the C-terminus of the receptor. Sections were then washed with TBS + 0.05 % 
Tween20, incubated with a biotinylated goat anti-rabbit antibody (1:400; DAKO, Eching, Germany) 
for 1 h at room temperature and afterwards treated with 3 % H2O2 for 20 min. Sections were rinsed in 
TBS + 0.05 % Tween20 and incubated for 60 min in horseradish peroxidase-labeled streptavidin 
(1:4000, Jackson Immunoresearch Laboratories, West Grove, Pennsylvania, USA). To visualize the 
staining, a nickel-intensified diaminobenzidine reaction was performed using a peroxidase substrate 
kit (Vector Laboratories, Burlingame, CA, USA). For immunolabeling of TRPV1 we used a 
polyclonal goat antibody recognizing the N-terminus of TRPV1 (1:200; Santa Cruz Biotechnology, 
CA, USA) and a biotinylated donkey anti-goat antibody (1:400; Vector Laboratories, Peterborough, 
UK). The protocol was essentially the same as described above. The specificity of the CB1 / TRPV1 
antibody binding was verified by means of CB1-KO and TRPV1-KO. 
We additionally performed a doublecortin immunostaining and a BrdU/NeuN immunofluorescence 
double staining as described previously (Jafari et al. 2012a). The following primary antibodies were 
used: polyclonal goat anti-doublecortin (1:300; Santa Cruz Biotechnology, Santa Cruz, California, 
USA) and rat anti-BrdU (1:300; AbD Serotec, Düsseldorf, Germany) combined with mouse 
monoclonal anti-NeuN (1:500; clone A60, Millipore, Temecula, USA).  
Secondary antibodies were biotinylated donkey anti-goat (1:550; Jackson Immunoresearch 
Laboratories, West Grove, Pennsylvania, USA) in combination with  peroxidase-labeled streptavidin 
(1:4000, Jackson Immunoresearch Laboratories, West Grove, Pennsylvania, USA) for doublecortin 
staining and carbocyanine 3-labeled donkey anti-rat (1:1000; Jackson Immunoresearch Laboratories, 
West Grove, Pennsylvania, USA), biotinylated donkey anti-mouse (1:500; Jackson Immunoresearch 
Laboratories, West Grove, Pennsylvania, USA) and carbocyanine 2-labeled streptavidin (1:1000; 
Jackson Immunoresearch Laboratories, West Grove, Pennsylvania, USA) for BrdU/NeuN staining. 
All sections were washed, mounted onto glass slides, air-dried, dehydrated, and cover-slipped with 
Entellan (Merck, Darmstadt, Germany). 
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Quantification and image analysis 
Labeled cells from the doublecortin and BrdU/NeuN stainings were counted across five brain sections 
per animal in the left and right dentate gyri in an area encompassing the entire dentate granule cell 
layer (upper and lower blades) and extending two cell body widths deep into the hilus. The sections 
were spaced 200 µm apart. The experimenter who performed the counting was blinded to the 
treatment conditions. 
We measured the number of doublecortin (DCX) -immunoreactive cells with an unbiased stereological 
analysis method, the optical fractionator, operated via the computer-assisted imaging system 
StereoInvestigator 6.0 (Microbrightfield Europe, Magdeburg, Germany). The hardware consisted of a 
Leica DMLB microscope (Leica, Bensheim, Germany), a Plan-Neofluar lens (Leica, Bensheim, 
Germany), a single chip charge coupled device (CCD) color camera (CX9000, Microbrightfield 
Europe, Magdeburg, Germany), and an AMD Athlon (tm) 64 Processor. The thickness of the counting 
frame was equal to the thickness of the section (minus guard zones from the top and bottom of the 
section). Only the immunoreactive cells that appeared within the counting frame and came into focus 
were counted. 
We counted BrdU/NeuN immunofluorescent positive cells on a computer monitor to improve 
visualization using a Hitachi HV-C20A (Hitachi, Japan) digital camera connected to a Zeiss LSM 510 
microscope (Carl Zeiss GmbH, Jena, Germany). Double-labeling was verified by careful analysis of 
the confocal z-series of multiple cells per animal. Counting of the fluorescent signals from BrdU-
immunoreactive cells as well as the number of double-labeled BrdU/NeuN cells was performed as 
described earlier (Pekcec et al. 2007). 
We analyzed CB1R and TRPV1 immunohistochemistry based on labeled area intensity using a 
computer image analysis system. The hardware consisted of an Olympus BH2 microscope with a 
Plan-Neofluar objective (Zeiss, Göttingen, Germany), a CCD color camera (Axiocam; Zeiss, 
Göttingen, Germany), and an AMD Athlon™ 64 processor-based computer with an image capture 
interface card (Axiocam MR Interface Rev.A; Zeiss, Göttingen, Germany). The analyzed images were 
1388x1040 pixels in dimension. Images were processed using KS400 image analysis software 
(Windows Release 3.0; Carl Zeiss Vision, Halbergmoos Germany). The detailed analysis methodology 
has been reported previously (Volk et al. 2004). Briefly, prior to image analysis, spatial calibration 
was performed and a signal threshold value was defined for each analyzed brain region (CA1 and CA3 
regions of the hippocampus and the inner third of the molecular layer of the dentate gyrus [the dentate 
gyrus was analyzed only for CB1 receptor immunohistochemistry]) to exclude background signals. 
Thus, the data obtained render information about the labeled area above the threshold. Due to very 
weak CB1R immunostaining in the polymorphic layer of the dentate gyrus, this area was analyzed 
only qualitatively and descriptively in five animals per group. 
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Statistics 
We performed statistical analysis of group differences using GraphPad Prism (Version 5.04, 
GraphPad, San Diego, CA, USA). Inter-group differences in kindling development were detected with 
the two-sided Mann Whitney U-test and the unpaired two-sided t-test, if necessary with Welch’s 
correction. Two-way ANOVA for repeated measurements (dependent factor: time, independent factor: 
treatment/genotype) was performed by Statistica, v5.0 (StatSoft (Europe) GmbH, Hamburg, 
Germany). Immunohistological data were analyzed by two-way ANOVA and was followed by an 
unpaired T-test to detect group differences. 
To detect statistical outliers, the Grubbs’ test was used. All data are given as mean values ± SEM, and 
a p < 0.05 was considered significant. 
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Results 
Kindling increases CB1R expression in the hippocampus, whereas TRPV1 expression remains 
unaltered 
Considering CB1Rs and TRPV1 as promising targets for the regulation of neuronal activity in 
epilepsies we investigated if seizures influence the density of CB1Rs and of TRPV1. Therefore, we 
analyzed CB1R expression in CamK-CB1 WT mice and TRPV1 expression in NMRI mice associated 
with or without seizure history in the hippocampal formation six days after the last kindled seizure. 
Non-kindled CamK-CB1 WT mice show the well-described expression pattern of CB1Rs in the 
analyzed brain areas (Tsou et al. 1997; Egertová and Elphick 2000; Monory et al. 2006). They densely 
express CB1Rs in the Ammon’s horn, especially in the stratum pyramidale in CA1 and CA3 fields. In 
the stratum oriens, a higher CB1R density was detected than in the stratum radiatum. In the dentate 
area, the molecular layer intensely expressed CB1Rs with highest density in the inner third, whereas 
the granule cell layer appears as a translucent band. The polymorphic layer of the dentate gyrus 
virtually lacked CB1R staining in low-power magnification. In a high resolution only very sparsely 
immunoreactive fibers were seen. At the junction of the granule cell layer and the polymorphic layer 
numerous intensely immunoreactive neurons were evident. CB1R immunoreactivity was always 
associated with the cell membrane and the neuronal somata remaining unstained. (Fig. 1 B-I, Supl. 
Fig. 2A, B). In samples of mice with seizure history, CB1R immunostaining proved to be much 
stronger throughout the hippocampus. The most striking difference was found in the Ammon’s horn. 
Kindled animals exhibited an increase of CB1R expression by 316% in the CA1-region and by 371% 
in the CA3-region (CA1 p = 0.0273; CA3 p = 0.0231; Fig. 1 A). In the molecular layer of the dentate 
gyrus CB1R immunostaining tended to be elevated, with an average increase of 271% (p = 0.069; Fig. 
1 A). In contrast, CB1R expression in the polymorphic layer of the dentate gyrus appeared comparable 
in both groups. 
Non-kindled NMRI mice show homogenous and weak to moderate TRPV1 immunoreactivity in cell 
bodies and in the cell membrane of hippocampal pyramidal cells (Supl. Fig. 1B, D-G). The 
immunoreactivity in the dentate gyrus was so weak that quantification was impossible (Supl. Fig. 1H-
I). Only unspecific TRPV1 immunoreactivity was observed in TRPV1-KO mice, confirming specific 
binding of the antibody (Supl. Fig. 1C). In samples of mice with seizure history, TRPV1 
immunostaining proved to be comparable in the CA1 (p=0.1988) and CA3 (p=0.4691) subfields of the 
hippocampus, when compared to non-kindled controls (Supl. Fig. 1A). 
 
The endocannabinoid system affects ictogenesis but not epileptogenesis 
CB1R deletion in principal neurons of the forebrain and in GABAergic forebrain neurons exerts 
opposing effects on seizure duration 
The conditional deletion of the CB1R gene in principal neurons of the forebrain but not in GABAergic 
interneurons (CamK-CB1 KO) caused in naïve animals a lowered afterdischarge threshold when 
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compared to wildtype controls (p = 0.0281, Fig. 2A). We observed the characteristic reduction of 
seizure thresholds after kindling acquisition in the CamK-CB1 WT and -KO mice (p = 0.0388, Fig. 
2A). 
The progression of the seizure severity was comparable in CamK-CB1 KO mice and in littermate 
controls. The mean number of stimulations to reach a generalized stage five seizure did not differ 
between the two groups (CamK-CB1 WT = 6.6 ± 0.82 and CamK-CB1 KO = 6.22 ± 0.66, p = 0.728, 
Fig. 2D). In CamK-CB1 KO the analysis of the cumulative afterdischarge duration exceeded that in 
littermate wildtype controls (p = 0.0128; Fig. 2G). We demonstrated a significant impact of the 
genotype on seizure duration (p = 0.007, Fig. 2E) and afterdischarge duration (p = 0.0051; Fig. 2F) by 
two-way ANOVA. However, after kindling acquisition seizure duration (p=0.2962; Fig. 2B) and 
afterdischarge duration (p=0.2783; Fig. 2C) are comparable in CamK-CB1 WT and KO mice. 
The deletion of CB1Rs in GABAergic cortical forebrain neurons (Dlx-CB1 KO) had no impact on 
either initial afterdischarge thresholds or post-kindling thresholds (initial p = 0.1778, post p = 0.1547; 
Fig. 2H). Kindling acquisition caused the characteristic threshold reduction (p = 0.0042, Fig. 2H). 
The progression of the seizure severity and the mean number of stimulations to reach a generalized 
stage five seizure was comparable in both groups (Dlx-CB1 WT n = 6.6 ± 0.8 and Dlx-CB1 KO n = 
7.2 ± 1.1, p = 0.6908; Fig. 2K). The analysis of seizure duration and afterdischarge duration revealed a 
reduced duration in Dlx-CB1 KO mice as compared to littermate controls (Fig. 2L, M). The 
cumulative afterdischarge duration was decreased in Dlx-CB1 KO mice (p = 0.0147) with a mean 
duration time of 176.9 ± 5.3 s when compared to Dlx-CB1 WT mice with a mean duration time of 
213.9 ± 10.0 s (Fig. 2N). Furthermore, we confirmed an impact of the genotype on seizure durations 
and on afterdischarge duration parameters (seizure duration: p < 0.0001; afterdischarge duration: p < 
0.001). Finally, after the kindling process was completed, the seizure duration (p = 0.0705; Fig. 2I) 
and the afterdischarge duration (p = 0.0477; Fig. 2J) tended to be lower in Dlx-CB1 KO mice.  
 
The CB1R antagonist rimonabant prolongs seizure duration 
Rimonabant treatment affected neither the initial afterdischarge threshold determined prior to the 
kindling process nor the post-kindling afterdischarge threshold (Fig. 3A). However, the seizure 
duration at post-kindling afterdischarge threshold determination reached higher levels in rimonabant-
treated animals as compared to the vehicle-treated group (p = 0.0025, Fig. 3B). A comparable trend 
was visible during pre-kindling threshold stimulation (p = 0.0656, data not shown). Furthermore, 
during pre- and post-kindling threshold determination, rimonabant treatment resulted in longer 
afterdischarge duration when compared to vehicle-treated controls (initial: p = 0.0114, data not shown, 
post p = 0.0027, Fig. 3C). We observed the characteristic kindling-associated reduction of 
afterdischarge thresholds in both groups (p = 0.0469; Fig. 3A). 
The development of seizure severity during kindling acquisition was comparable in rimonabant- and 
vehicle-treated mice. The mean number of stimulations to reach a generalized stage five seizure did 
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not differ between the rimonabant- (n = 11.2 ± 1.5) and vehicle-treated groups (n = 14.3 ± 1.5, p = 
0.1599; Fig. 3D). However, the relative cumulative afterdischarge duration in rimonabant-treated mice 
exceeded that in vehicle-treated animals (p = 0.0008; Fig. 3G). In addition, the data revealed an 
impact of the treatment with rimonabant on prolonging motor and electrographic seizure activity 
(seizure duration: p = 0.0001; afterdischarge duration: p = 0.0001; Fig. 3E, F). 
 
The endovanilloid system has no impact on epileptogenesis and on ictogenesis  
Genetic knock out of TRPV1 and the TRPV1 antagonist SB366791 has no relevant impact on seizure 
parameters 
The initial and post-kindling afterdischarge threshold was not affected by TRPV1 deficiency and 
pharmacological antagonism (Fig. 4A, H). Kindling acquisition caused the characteristic kindling-
associated reduction of afterdischarge thresholds in TRPV1-WT and –KO (p = 0.0181, Fig. 4A) 
Genetic deletion of TRPV1 had no impact on the development of seizure severity or the duration of 
motor and electrographic seizure activity (Fig. 4D, E, F). The mean number of stimulations to reach a 
generalized stage five seizure was comparable between WT and KO mice (TRPV1-WT n = 4.5 ± 0.7 
and TRPV1-KO n = 4.8 ± 0.5, p = 0.7696; Fig. 4D). 
Kindling acquisition also proved to be comparable in SB366971-treated and vehicle-treated mice (Fig. 
4K). The mean number of stimulations to reach a generalized stage five seizure did not differ between 
SB366791-treated mice (n= 10.5 ± 0.9) and vehicle-treated mice (n = 11.1 ± 1.2, p = 0.689; Fig. 4K). 
There was no statistically specific difference between SB366971-treated and vehicle-treated mice 
regarding seizure duration and afterdischarge duration (Fig. 4L, M). 
Surprisingly, seizure duration and afterdischarge duration during threshold determination after the 
kindling process were significantly longer in TRPV1-KO mice (seizure duration: p = 0.0341, 
afterdischarge duration: p = 0.0061, Fig. 4B, C). In contrast, pharmacological antagonism exerted no 
effect on seizure duration during post-kindling threshold determination (seizure duration: p = 0.7147 
afterdischarge duration: p = 0.8187, Fig. 4I, J). 
 
The endocannabinoid system has no impact on neurogenesis during kindling acquisition 
Kindling increases hippocampal neurogenesis without interaction of the endocannabinoid system 
Conditional deletion of CB1Rs in principal neurons of the forebrain did not affect neuronal progenitor 
cells or the fate of newborn neurons in the hippocampus of CamK-CB1 KO mice.  
However, we identified kindling–associated alterations in hippocampal neuronal progenitor cells and 
newborn neurons in the hippocampus of knockout mice and their littermate controls. We analyzed the 
number of neuronal progenitor cells six days after the last kindled seizure and found a kindling-
induced increase by 110 and 176% in CamK-CB1 WT and CamK-CB1 KO mice, respectively (Fig. 
5A, B, F). Kindling also increased the number of BrdU-positive labeled cell nuclei in the dentate 
gyrus by 118 % in CamK-CB1 WT (p = 0.0057) and by 139 % in CamK-CB1 KO mice (p < 0.001, 
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data not shown). An increase in the total number of newborn neurons (BrdU/NeuN double-labeled) 
was confirmed in the two kindled groups when compared to non-kindled controls (CamK-CB1 WT p 
= 0.0118 and CamK-CB1 KO p = 0.0048; Fig. 5C, D, E, G). In all four groups, 21-23 % of the BrdU-
immunoreactive cells co-expressed the neuronal marker NeuN (Fig. 5H). 
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Discussion 
Seizures increase CB1R density in the pyramidal cell layer of the hippocampus, whereas TRPV1 
expression remains unaltered 
In the present study, we demonstrate that kindling stimulations increased the CB1R density in the 
pyramidal cell layer. No respective response was observed in other sub-regions of the hippocampus, 
including the polymorphic layer. Similar findings have been reported for different mouse models of 
epilepsy and in human patients with epilepsy (Magloczky et al. 2010; Karlocai et al. 2011; Bojnik et 
al. 2012). Repeated electrically-induced seizures form a stable hyperexcitable network, which is 
associated with permanent enhanced seizure susceptibility and with cellular and molecular alterations. 
These alterations mimic the pathophysiological findings of temporal lobe epilepsy (Goddard et al. 
1969). 
The hippocampal up-regulation of CB1Rs may be a compensatory mechanism of excitatory neurons to 
strengthen the negative feedback loop of the endocannabinoid system and to down-regulate 
neurotransmitter release. Thus, the endocannabinoid system on these neuronal subpopulations may 
serve as a protective endogenous mechanism against seizure induced excitotoxicity as proposed in 
earlier studies (Marsicano et al. 2003; Wallace et al. 2003; Monory et al. 2006). However, our results 
differ from the studies of Falenski et al. (2009) and Weyeth et al. (2010), who found a reduced 
expression of CB1Rs or at least a reduction in certain neuronal subpopulations. This divergence could 
be a result of the differences between the epilepsy models (chemical versus electric models). 
We identified weak to moderate TRPV1 expression in pyramidal cells in the CA1 and CA3 subfields 
of the hippocampal formation, whereas expression levels in the dentate gyrus were extremely low. 
Accumulating evidences from experiments using the specific radioactive ligand [3H]resiniferatoxin, 
mRNA probes and immunohistological techniques support the idea of a widespread distribution of 
TRPV1 in the central nervous system (Mezey et al. 2000; Roberts et al. 2004; Toth et al. 2005; Han et 
al. 2013). In all these studies TRPV1 protein was detected in the hippocampus, however, quantitative 
measurements of TRPV1 expression lead to variable outcomes. Toth et al. (2005) identified the 
hippocampus as the region with highest level of TRPV1 immunoreactivity, whereas Han and 
colleagues (2013) found the least amount of TRPV1 immunoreactivity in this brain region. The same 
discrepancies are found for TRPV1 expression in hippocampal subregions. Toth et al. (2005) detected 
the strongest TRPV1 immunoreactivity in the cellular layer of the dentate gyrus and in the CA1 
region. In contrast another study reported densest binding of [3H]resiniferatoxin in CA3 and in the 
dentate gyrus (Roberts et al. 2004). The analysis of a TRPV1 reporter mouse revealed TRPV1 
expression in the hippocampus exclusively in Cajal-Retzius cells (Cavanaugh et al. 2011). Thus, the 
expression profile of TRPV1 in the brain has yet not been finally clarified. 
In contrast to increased CB1R expression due to repetitive seizures, TRPV1 expression is unaltered in 
the hippocampus of mice with seizure history. There is only one study based on data from human 
patients with clinical manifestations of temporal lobe epilepsy, which reports an increased TRPV1 
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expression in the hippocampus of these patients (Sun et al. 2013). Here, we used an animal model of 
epileptogenesis. Possibly, changes in TRPV1 expression levels may occur later in the course of the 
disease and are therefore not manifested during epileptogenesis. Further studies in different animal 
models of epileptogenesis as well as in chronic animal models with spontaneous seizures are necessary 
to give a definite statement about TRPV1 expression levels and their pathophysiological relevance in 
epilepsy and epileptogenesis.  
 
The endocannabinoid-system has an impact on seizure susceptibility and on ictogenesis dependent on 
the neuronal subpopulation being modulated 
In naïve CamK-CB1 KO mice we detected lower initial afterdischarge thresholds as compared to 
littermate controls, but comparable initial afterdischarge thresholds were observed in naïve Dlx-CB1 
KO mice. Our findings are in line with a previous study demonstrating increased susceptibility to 
kainic acid-induced seizures as a consequence of CB1R deletion in glutamatergic forebrain neurons 
(Monory et al. 2006). The CB1R KO mice used in our study lack CB1Rs in principal neurons of the 
forebrain, which in the hippocampus are mainly glutamatergic. Therefore, the glutamate release is not 
endogenously regulated when activated on demand, resulting in increased glutamate levels, enhanced 
excitation, and decreased seizure susceptibility. Our data show that lack of CB1R, especially in 
principal forebrain neurons, lowers the afterdischarge threshold in naïve animals, implying that the 
excitability of the neuronal system in these mice already differs before kindling. In contrast, the 
progression of seizure severity during kindling was comparable in both groups arguing against any 
major impact of CB1R on principal forebrain neurons on the formation of the hyperexcitable kindled 
network. However, the interpretation of our findings is limited by the use of suprathreshold 
stimulation current during kindling. This might hide possible genotype/ treatment differences during 
kindling development due to the ceiling effect.  
We found that the lack of CB1Rs in CamK-CB1 KO mice as well as antagonism of CB1Rs causes 
longer seizure duration, whereas a CB1R knock out in GABAergic neurons of the forebrain results in 
shorter seizure duration. This can be explained by the opposing functions of neuronal subpopulations 
targeted by the modulation strategies. Due to the negative feedback loop, CB1R knock out in the 
forebrain results in prolonged excitation of glutamatergic neurons and consecutively in longer seizure 
duration. In contrast, a lack of CB1Rs in GABAergic neurons increases GABA release and therefore 
the inhibitory component of neuronal communication, leading to shorter seizure duration. These 
results provide evidence that GABAergic interneurons play a role in the CB1R dependent control of 
electrically-induced behavioral seizures by the endocannabinoid system. Taking into consideration that 
cell-type-unspecific pharmacological blockade of CB1Rs resulted in prolonged seizures during 
kindling acquisition, we conclude from these experiments that endocannabinoid signaling in 
hippocampal glutamatergic principal neurons overrules that in GABAergic interneurons during seizure 
activity. This is probably related to excessive seizure-associated glutamatergic signaling (Blumcke et 
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al. 2000; Kandratavicius et al. 2013). However, lack of CB1R in GABAergic forebrain neurons caused 
a decrease in motor and electrographic seizure durations after completing the kindling process. Thus, 
GABAergic signaling might be responsible for long lasting protective effects in a hyperexcitable 
neuronal network.  
The endocannabinoid system has been suggested to be an important endogenous mechanism for 
seizure duration and termination (Wallace et al. 2003; Deshpande et al. 2007), but the significance of 
neuronal subtypes in the context of epileptogenesis and ictogenesis has never been studied in detail in 
a chronic epilepsy model. In the present study, we not only blocked CB1Rs pharmacologically but 
also used genetic tools to analyze the cell-type-specific mechanism of seizure termination. To our 
knowledge, we have shown for the first time that conditional CB1R knockout in GABAergic neurons 
of the forebrain cause shorter seizure durations. These results confirm that the endocannabinoid 
signaling cascade plays a major role in seizure termination and duration through activation of CB1Rs. 
In a kainic acid-induced seizure model, Monory et al. (2006) revealed that CB1Rs on hippocampal 
glutamatergic but not GABAergic neurons are required for protection against excitotoxic seizures. In 
another study CB1R function was reconstituted exclusively in dorsal telencephalic glutamatergic 
neurons. The rescue of CB1 in this brain area prolonged the time course of depolarization-induced 
suppression of excitation in the amygdala, indicating that CB1Rs in dorsal telencephalic glutamatergic 
neurons control neuronal functions (Ruehle et al. 2013). Furthermore, Guggenhuber et al (2010) 
conditionally overexpressed CB1Rs in pyramidal and mossy cells and demonstrated protective effects 
against seizures. The authors concluded that conditionally reduced transmitter release can decrease 
seizure intensity and exert neuroprotective effects (Guggenhuber et al. 2010).  
Our data provide further evidence of the functional importance of the localization of CB1Rs and 
indicate that a specific antagonism at CB1Rs on GABAergic forebrain neurons or selective agonism at 
CB1Rs on glutamatergic forebrain neurons could be a safeguard against excessive network activity 
and therefore an antiepileptogenic strategy.  
Several new revolutionary techniques, like DREADDs (designer receptors exclusively activated by 
designer drugs) and optogenetic tools delivered via local administration of viral vectors, open up 
tremendous future potential to selectively target specific neuronal subpopulations (Conklin et al. 2008; 
Deisseroth 2011; Farrell and Roth 2013). These techniques are still in their infancy and if they make 
their way into clinical use and may be applicable for targeting the endocannabinoid system is still a 
matter of question. So far the only technique to offer event- and site-specific effects is based on 
inhibition of endocannabinoid degrading enzymes, fatty acid amide hydrolase and monoacylglycerol 
lipase. The major sites of action of these inhibitors are those synapses with enhanced signaling and 
excessive on-demand production of endocannabinoids. However, a highly selective targeting of 
GABAergic or glutamatergic neuronal subpopulations is not possible with this approach. During 
epileptic seizure activity with excessive activation of glutamatergic synapses, the net effect of CB1R 
signaling on hippocampal projectory neurons apparently naturally predominates, indicating that a cell-
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type-specific treatment might not be necessary. Administration of CB1R agonists might further 
enhance the negative feedback, thus supporting the endogenous mechanism for seizure termination. In 
future studies, it might be of interest to assess the efficacy of CB1R agonists in chronic animal models 
with spontaneous seizures. It is conceivable that targeting the endocannabinoid system could be a new 
therapeutic strategy, especially for long-lasting refractory status epilepticus and cluster seizures. 
 
The endocannabinoid system has no crucial role in the generation of a hyperexcitable neuronal 
network 
Our data demonstrate that neither genetic nor pharmacological modulation of the endocannabinoid 
system affects the development of generalized seizures during kindling acquisition when compared to 
the respective control groups. Previous studies addressing a role of CB1Rs during epileptogenesis 
have not revealed consistent findings. Echegoyen and colleagues reported a disruption of the 
epileptogenic process by a single application of rimonabant in a model of post-traumatic brain injury, 
when applied within a short therapeutic time window (Echegoyen et al. 2009). The antiepileptogenic 
effect indicated by these findings has not been substantiated yet by follow-up studies. In apparent 
contrast, Van Riijn et al. (2011) reported that the CB1R antagonist rimonabant can exert a 
proepileptogenic effect after chronic administration in naïve rats (van Rijn et al. 2011). Another study 
in the kainate model of temporal lobe epilepsy did not report relevant effects of rimonabant on 
epileptogenesis (Dudek et al. 2010). Considering these controversial findings, it is obviously necessary 
to further explore the role of CB1Rs in epileptogenesis in more detail. The use of conditional 
mutagenesis allowed us to precisely analyze the functional consequences of CB1R loss in different 
neuronal subpopulations of the forebrain in direct comparison with pharmacological antagonism. 
Neither genetic nor pharmacological targeting exerted any impact on kindling-associated progression 
of seizure severity, thus, arguing against a crucial role of CB1Rs during epileptogenesis. 
In addition, we observed the characteristic reduction of seizure thresholds after kindling acquisition in 
all experiments, in which the endocannabinoid system was modulated either genetically or 
pharmacologically. Since the CB1R antagonist rimonabant was administered continuously during the 
kindling paradigm and not only to already kindled animals, any changes in the post kindling 
afterdischarge threshold might be a result of a continuous lack of the involvement of the 
endocannabinoid system during epileptogenesis. A similar situation occurs logically in CB1R deficient 
mice, further arguing against a relevant role of the endocannabinoid system in epileptogenesis. 
 
The endocannabinoid system has no effect on seizure-associated alterations in neurogenesis 
Evidence exists that the endocannabinoid system is involved in the modulation of cell proliferation, 
differentiation, maturation and survival of newborn neurons (for review see (Fogaca et al. 2013)). 
Aguado and colleagues (2005) provided evidence that neuronal progenitor cells possess a functionally 
endocannabinoid system and that the system remains functional active in adult brain progenitor cells. 
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The molecular constituents being involved in neuronal development and adult neurogenesis are the 
endogenous ligands anandamide and 2-AG, CB1R and CB2R as well as the AEA-degrading enzyme 
fatty acid amide hydrolase (FAAH) and the 2-AG synthesizing enzyme diacylglycerol lipases (Aguado 
et al. 2005; Goncalves et al. 2008). Our data show that CB1R expression is elevated due to kindling 
and one would assume temporary elevated endocannabinoid levels due to on demand activation of the 
endocannabinoid system. We know from the literature that neurogenesis requires CB1Rs and that 
enhanced endocannabinoid levels increase hippocampal cell proliferation. Thus, we expected 
endocannabinoid system dependent alterations. Surprisingly, in the present study, proliferation and 
generation of newborn neurons were induced by repeated seizures regardless of the genetic modulation 
of the endocannabinoid system. It has also been shown that the kindling process itself leads to 
increased hippocampal neurogenesis (Parent et al. 1998; Aguado et al. 2005; Pekcec et al. 2011; Jafari 
et al. 2012b), here pointing toward kindling associated alterations of cell proliferation. These data 
suggest that the endocannabinoid system plays no role in the disease-associated modulation of 
neurogenesis in the kindling model of temporal lobe epilepsy.  
 
The endovanilloid system has no effects on the different seizure parameters 
We found that neither genetic knockout of TRPV1 nor pharmacological antagonism alters seizure 
susceptibility, seizure progression or seizure duration before and during kindling acquisition. 
However, afterdischarge duration and motor seizure duration during seizure threshold determination 
after the kindling process proved to be significantly prolonged in genetically modified animals. 
Considering that TRPV1 seem to regulate glutamate release in an activity-dependent manner and can 
strongly potentiate the duration of postsynaptic spiking (Peters et al. 2010; Shoudai et al. 2010), this is 
a surprising result. TRPV1 are expressed, among others, in the hippocampus (Roberts et al. 2004; Toth 
et al. 2005; Han et al. 2013) and in contrast to our own results, an increase of TRPV1 protein 
expression has been described in the hippocampus of mice (Bhaskaran and Smith 2010) as well as in 
brain tissue from human patients with temporal lobe epilepsy (Sun et al. 2013). We expected an 
inhibitory effect of TRPV1 antagonism or genetic deficiency on hyperexcitability and acute seizures in 
the kindling model. Recent studies in chemical animal models of temporal lobe epilepsy have 
suggested TRPV1 as an interesting target site for epilepsy treatment. Neonatal TRPV1 deficient mice 
are less susceptible to PTZ-induced seizures following hyperthermia (Kong et al. 2014). Moreover, 
agonists like capsaicin and OLDA enhanced epileptiform activity, whereas antagonists like 
capsazepine and AMG9810 abolished these effects (Bhaskaran and Smith 2010; Gonzalez-Reyes et al. 
2013; Shirazi et al. 2014). Capsazepine is a competitive antagonist of capsaicin with species-specific 
activity (McIntyre et al. 2001; Savidge et al. 2002). Furthermore it inhibits acetylcholine receptors 
(Liu and Simon 1997), voltage-gated Ca2+-channels (Docherty et al. 1997) and hyperpolarization-
activated cyclic nucleotide-gated channels (Gill et al. 2004). Thus, it is far from an ideal specific 
pharmacological tool. Therefore we used SB366791, which is a more selective and potent TRPV1 
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antagonist as compared to capsazepine (Gunthorpe et al. 2004; Varga et al. 2005). Surprisingly, 
neither the genetic modulation nor the pharmacological antagonism indicated relevant TRPV1-
mediated effects, strongly arguing against a role of the endovanilloid system in ictogenesis. However, 
the prolonged seizure and afterdischarge duration of TRPV1 KO mice after the kindling process 
indicates that TRPV1 might contribute to seizure termination once a hyperexcitable neuronal network 
has been formed in the epileptic brain. In line with this idea is the recent study of Shirazi and 
colleagues (Shirazi et al. 2014) who reported reduced electrographic seizure duration in fully-kindled 
mice when treated with a TRPV1 antagonist. However, this assumption needs to be studied in more 
detail, also considering that pharmacological antagonism did not exert a comparable effect on the post-
kindling seizure durations.  
Based on earlier studies indicating opposing effects of the endocannabinoid and endovanilloid 
signaling on ictogenesis, Bhaskaran and Smith (2010) raised safety concerns regarding the application 
of pharmacological strategies, which non-selectively affect endocannabinoid signaling in epilepsy 
patients. Our findings rather indicate that effects mediated by TRPV1 can be neglected, as they are 
unlikely to affect the efficacy and tolerability of respective pharmacological approaches.  
 
Conclusion 
The aim of this study was to evaluate whether targeting the endocannabinoid and endovanilloid 
systems might (1) affect epileptogenesis, (2) have an impact on ictogenesis and (3) exert disease-
modifying approaches. Our data indicate that the endocannabinoid system has no crucial role on the 
generation of a hyperexcitable neuronal network, but affects seizure duration depending on the 
neuronal subpopulation being modulated. CB1R deficiency in principal neurons of the forebrain 
causes longer seizure duration, whereas CB1R deletion in GABAergic neurons of the forebrain results 
in shorter seizure duration. We deduce that the endocannabinoid system is involved in seizure 
termination as an important endogenous mechanism.  
In addition, the data suggest that TRPV1 do not play a major role epileptogenesis, and that the 
endovanilloid system is not strongly involved in ictogenesis or seizure termination. 
These findings suggest that the endocannabinoid system can be considered as a promising target for 
decreasing seizure duration and supporting the endogenous mechanisms of seizure termination. 
Respective strategies are of particular interest for the management of long-lasting refractory status 
epilepticus and cluster seizures. 
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Figures 
Figure 1: 
CB1R expression in the 
hippocampus. A. Kindling 
increases the CB1R density in 
the CA1 and CA3 regions of the 
hippocampal formation of 
CamK-CB1 WT mice. The 
distribution of CB1Rs in the 
hippocampus of CamK-CB1 WT 
mice is illustrated in B and in 
comparison a CB1-KO mice as 
indicated in C with the lack of 
specific staining of CB1Rs 
(negative control). Magnification 
of CA1 (D, E), CA3 (F, G) and 
dentate gyrus (H, I): In non-
kindled control animals the 
specific CB1R expression pattern 
can be seen in CA1 and CA3 
stratum pyramidale and radiatum 
(D, F) and in the molecular layer 
of the dentate gyrus (H). In 
kindled mice, the CB1R 
immunostaining is more intense 
throughout the hippocampus (E, 
G, I). In the dentate gyrus of 
kindled mice, stained fibers 
establish a dense meshwork (I). Non-kindled CamK-CB1 WT n=8, kindled CamK-CB1 WT n=9; s.o.: 
str. oriens, s.p. str. pyramidale, s.r.: str. radiatum, s.m.: str. moleculare, s.g.: str. granulosum. 
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Figure 2: 
 
Effects of genetic modulation of the endocannabinoid system on afterdischarge threshold (ADT), 
seizure severity (SS), seizure duration (SD), and afterdischarge duration (ADD) during and after 
kindling acquisition. A-G: CamK-CB1 KO mice versus littermate controls. A Pre- and post-kindling 
thresholds: note the significantly lower seizure threshold in naïve CamK-CB1 KO mice when 
compared to naïve controls. B Seizure duration and C afterdischarge duration after kindling 
acquisition. D CB1R knockout in principal neurons of the forebrain fails to have an impact on SS over 
time. However, motor seizure duration (E) and afterdischarge duration (F) are increased. The relative 
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cumulative afterdischarge duration (cum ADD) reflects the overall increase in ADD in mice with 
CB1R deletion in principal neurons of the forebrain (G). H-N: Dlx-CB1 KO mice versus littermate 
controls. F Pre- and post-kindling thresholds. I Seizure duration and J afterdischarge duration are 
reduced in Dlx-CB1 KO mice after kindling acquisition. K CB1R deletion in GABAergic forebrain 
neurons fails to have an impact on SS, but decreased the seizure duration (L) and the afterdischarge 
duration (M) when compared to control animals. N A decrease of the relative cumulative 
afterdischarge duration was observed in mice with CB1R deletion in GABAergic forebrain neurons. 
All data are given as mean ± SEM, * p < 0.05, two-way ANOVA for repeated measurement and 
unpaired student’s t-test. CamK-CB1 WT n = 10, CamK-CB1 KO n = 10, Dlx-CB1 WT n = 8, and 
Dlx-CB1 KO n = 6. 
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Figure 3: 
Effects of pharmacological modulation 
of the endocannabinoid system with 
rimonabant on afterdischarge 
threshold (ADT), seizure severity (SS), 
seizure duration (SD), and 
afterdischarge duration (ADD) during 
and after kindling acquisition. A 
Rimonabant- versus vehicle-treated 
animals pre- and post-kindling. B Seizure 
duration and C afterdischarge duration 
after kindling acquisition. D 
pharmacological modulation with 
rimonabant fails to have an impact on 
seizure severity over time. E, F However, 
rimonabant treatment increased the 
duration of epileptic seizures. G The 
relative cumulative afterdischarge 
duration (cum ADD) reflects the overall 
increase in ADD in rimonabant-treated 
mice. All data are given as mean ± SEM, 
* p < 0.05, two-way ANOVA for 
repeated measurement and unpaired 
student’s t-test. Vehicle n = 9 and 
rimonabant n = 11. 
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Figure 4: 
 
Effects of genetic and pharmacological modulation of the endovanilloid system on afterdischarge 
threshold (ADT), seizure severity (SS), seizure duration (SD), and afterdischarge duration 
(ADD) during and after kindling acquisition. 
A-G Genetic modulation: TRPV1-KO mice versus their respective littermate controls. H-N 
Pharmacological modulation: SB366791-treatment versus vehicle-treated animals. The endovanilloid 
system fails to have an impact on any of the different seizure parameters during and after kindling 
acquisition. However, TRPV1-KO mice exhibit significantly longer motor and 
electroencephalographic seizure durations (B, C) after the kindling process. All data are given as mean 
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± SEM, * p < 0.05, unpaired student’s t-test and two-way ANOVA for repeated measurements. 
Vehicle n = 9, SB366791 n = 12, TRPV1-WT n = 13, and TRPV1-KO n = 8. 
 
Figure 5: 
 
Neurogenesis in the hippocampus of kindled versus non-kindled mice: A-B. Doublecortin (DCX) 
immunostaining of neuronal progenitor cells and early postmitotic neurons in the dentate gyrus of the 
hippocampus for representative animals of CamK-CB1 WT control (A) and CamK-CB1 WT kindled 
(B) mice. C-E. Representative BrdU (red) and neuronal (NeuN - green) nuclei in the dentate gyrus of 
non-kindled (C) and kindled (D) animals visualized via immunofluorescent double staining. Cells 
identified as newborn neurons (white arrows) express NeuN and incorporated BrdU, thus appearing in 
yellow. E The figure illustrates a high magnification of a BrdU/NeuN double-labeled cell of a kindled 
mouse within the dentate gyrus. Scale bar: 50µm F-G. Analysis of DCX-positive cells and 
BrdU/NeuN-positive cells in the dentate gyrus of the hippocampal formation. Kindling significantly 
increased the number of neuronal progenitor cells (F) and newborn neurons (G). H BrdU/NeuN co-
expression out of all BrdU-labeled cells is comparable in all four groups. All data are given as mean ± 
SEM, * p < 0.05, two-way ANOVA. CamK-CB1 WT n = 10, and CamK-CB1 KO n = 10. 
 
Research articles  49 
Supplementary information 
Supplementary Figure 1: 
 
TRPV1 expression in the hippocampus. A. The labeled area of TRPV1 immunoreactivity is not 
affected by seizures. The interindividual variance was high within the animal groups. The distribution 
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of TRPV1 in the hippocampus of NMRI mice is illustrated in B, whereas no labeling was observed in 
TRPV1-KO mice (C), demonstrating the specificity of the antibody (negative control). Magnification 
of CA1 (D, E), CA3 (F, G) and dentate gyrus (H, I): Specific TRPV1 expression can be seen in the 
cytoplasm of CA1 and CA3 pyramidal neurons, which show moderate to weak immunoreactivity (D-
G). Kindling did not affect TRPV1 expression in CA1 and CA3 subfields of the hippocampus. In the 
dentate gyrus only weak immunoreactivity was detected (I). Non-kindled NMRI n=8, kindled NMRI 
n=8; s.o.: str. oriens, s.p. str. pyramidale, s.r.: str. radiatum, s.g.: str. granulosum. 
 
Supplementary Figure 2: 
 
CB1R expression in the hilar region of the dentate gyrus. Note the low immunoreactivity in the 
granule cell layer and in the hilar region. Some more intensely stained neurons are located at the 
transition zone of the granule cell layer and the polymorphic layer of the dentate gyrus. The CB1R 
expression pattern and density are comparable in non-kindled mice (A) and kindled CamK-CB1 mice 
(B). s.g.: stratum granulosum; po.: polymorphic layer. 
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Abstract 
Endocannabinoids, including 2-arachidonoylglycerol (2-AG), activate presynaptic cannabinoid type 1 
receptors (CB1R) on inhibitory and excitatory neurons, resulting in a decreased release of 
neurotransmitters. Event-specific activation of the endocannabinoid system by inhibition of the 
endocannabinoid degrading enzymes may offer a promising strategy to selectively activate CB1Rs at 
the site of excessive neuronal activation with the overall goal to prevent the development epilepsy.  
The aim of this study was to investigate the impact of monoacylglycerol lipase (MAGL) inhibition on 
the development and progression of epileptic seizures in the kindling model of temporal lobe epilepsy. 
Therefore, we selectively blocked MAGL by JZL184 (8 mg/kg, i.p.) in mice to analyze the effects of 
increased 2-AG levels on kindling acquisition and to exclude an anticonvulsive potential.  
Our results showed that JZL184 treatment significantly delayed the development of generalized 
seizures (p=0.0066) and decreased seizure (p<0.0001) and afterdischarge duration (p<0.001) in the 
kindling model of temporal lobe epilepsy, but caused only modest effects in fully-kindled mice. 
Moreover, we proved that JZL184 treatment had no effects in conditional CB1R knockout mice	  
lacking expression of the receptor in principle neurons of the forebrain. 
In conclusion, the data demonstrate that indirect CB1R agonism delays the development of 
generalized epileptic seizures, but has no relevant acute anticonvulsive effects. Furthermore, we 
confirmed that the effects of JZL184 on kindling progression are CB1R mediated. Thus, the data 
indicate that the endocannabinoid 2-AG might be a promising target for an anti-epileptogenic 
approach.  
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Keywords 
epileptogenesis; endocannabinoid system; fatty acid amide hydrolase; FAAH; anandamide 
 
Highlights 
• Event- and side-specific activation of CB1Rs. 
• JZL184 delays the development of generalized seizures. 
• JZL184 has no anticonvulsive potential. 
• Effects of JZL184 are dependent on CB1R expression in principle forebrain neurons. 
 
Abbreviations: 
2-AG - 2-arachidonylglycerol 
CB1R- cannabinoid type 1 receptor 
MAGL - monoacylglycerol lipase 
SS – Seizure severity 
SD – Seizure duration 
ADD – Afterdischarge duration 
ADT – Afterdischarge threshold 
Cum ADD - cumulative afterdischarge duration 
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Introduction 
Anandamide and 2-arachidonylglycerol (2-AG), the two most studied endocannabinoids in the brain, 
are small lipid molecules, which retrogradely traverse the synapse and act presynaptically on 
metabotropic cannabinoid type 1 receptors (CB1Rs) (Kreitzer and Regehr 2001; Maejima et al. 2001; 
Wilson and Nicoll 2001). Activation of CB1Rs inhibit adenylyl cyclase and voltage-gated Ca2+ 
channels, resulting in a decreased release of neurotransmitters, thus modulating neuronal excitation 
and inhibition (Bidaut-Russell et al. 1990; Sugiura et al. 1997; Lauckner et al. 2005). As a 
consequence, activation of the endocannabinoid system may be a safeguard against hyperexcitability, 
acute seizures and excitotoxity (Ameri and Simmet 2000; Marsicano et al. 2003; Monory et al. 2006), 
raising the idea to slow down or even to prevent the development or progression of epilepsy. This is of 
particular interest, when considering that during excessive excitation endocannabinoid signaling has 
stronger effects on cortical principal neurons than on GABAergic interneurons (von Rüden et al. 
2014). Therefore, the endocannabinoid system is discussed as a potential target for the prevention of 
epilepsy (Hofmann and Frazier 2013). The process of epilepsy development (= epileptogenesis) refers 
to molecular and cellular alterations which transform a physiological neuronal network into an 
epileptic state, with an increased risk of recurrent spontaneous seizures (Goldberg and Coulter 2013). 
The detailed etiology of epileptogenesis and if the endocannabinoid system may be involved in 
epileptogenesis remains still incompletely understood.  
There are only few experimental studies in rodents which indicate anti-epileptogenic properties of 
direct CB1R activation (Bhaskaran and Smith 2010; Wendt et al. 2011). Recently, we evaluated the 
impact of the CB1R agonist WIN55.212-2 as well as of the indirect agonist URB597 on kindling 
progression (Wendt et al. 2011). WIN55.212-2 delayed kindling acquisition whereas URB597, which 
inhibits the catabolic enzyme fatty acid amide hydrolase and thereby reduces the degradation of 
anandamide, had no effect on the generation of a hyperexcitable neuronal network. In contrast to 
anandamide, 2-AG acts as a full agonist on CB1Rs and exhibits higher CB1R efficacy (Sugiura et al. 
1999; Sugiura et al. 2000; Sugiura et al. 2006). A molecular and morphological study of mossy cell-
granule cell synapses, revealed that 2-AG mediates retrograde signaling at these synapses and may 
reduce the excitability of granule cells and prevent seizures (Uchigashima et al. 2011). 
Although these experimental data are only limited, they strongly suggest a potential therapeutic role 
for the endocannabinoid 2-AG in epilepsy. However, there is, to our knowledge, no information about 
the impact of 2-AG on seizure thresholds or on the progression of seizure development in epilepsy. 
Considering this information, it is of particular interest to evaluate whether increased 2-AG levels 
affect these parameters in a chronic epilepsy model with excellent predictive validity for temporal lobe 
epilepsy.  
The aim of this study is to evaluate if pharmacological inhibition of monoacylglycerol lipase (MAGL) 
by JZL184 has an impact on the progression of epileptic seizures in the kindling mouse model of 
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temporal lobe epilepsy and to demonstrate that JZL184-mediated effects are CB1R dependent. For this 
purpose the indirect CB1R agonist JZL184 was used. JZL184 potently and selectively inhibits the 2-
AG degrading enzyme MAGL and this results in increased 2-AG levels up-to an 8-fold (Long et al. 
2009). This strategy offers a clear benefit compared with direct CB1R agonism namely event-specific 
effects, which are based on inhibition of the endocannabinoid degrading enzyme at CB1Rs localized 
on excessively activated glutamatergic synapses. 
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Methods 
Animals 
Animal experiments have been performed in accordance with the EU directive 2010/63/EU, and with 
the German Animal Welfare act. They were approved by the responsible government (license numbers 
55.2-1-54-2532-93-11 and 55.2-1-54-2532-173-11). Male mice with a body weight of 21-15g were 
used in all experiments and maintained in standard conditions with food and water ad libitum (24–
25°C; humidity 50–60%; lights on from 7am – 7pm). NMRI mice were acquired from Harlan 
Netherlands (Horst, Netherlands). CB1f/f;CaMKIIαCre mice (CamK-CB1 KO) and their respective wildtype 
littermate controls (CamK-CB1 WT) were bred at the Max Planck Institute of Biochemistry 
(Martinsried, Germany). These mice were derived from cre-negative mothers and cre-positive fathers 
(CamK-CB1) and were genotyped by PCR as described previously (Marsicano et al. 2003). They lack 
CB1Rs in principal forebrain neurons. All mice were allowed to habituate to the new environmental 
conditions for at least one week. 
 
Electrode implantation 
Stereotactical implantation of the kindling electrode into the right amygdala was performed as 
described previously (Jafari et al. 2012). The electrode consists of teflon-isolated stainless steel with a 
diameter of 280 µm. Mice were anesthetized with chloral hydrate (400 mg/kg in 10 ml saline i.p., 
Merck KGaA, Darmstadt, Germany) and bupivacaine (5 ml/kg s.c., Jenapharm®, Mibe, GmbH, 
Brehna). For analgesia meloxicam (1mg/kgm, s.c. Metacam®, Boehringer-Ingelheim, Ingelheim, 
Germany) was administered 30 min prior to and 24 h post-surgery. The stereotaxic coordinates in 
millimeter relative to bregma according to the atlas of Paxinos and Franklin (2004) were AP -1.0, L 
+3.2, DV -5.3 (NMRI) and AP -1.2, L +3.5, DV -5.2 (CamK-CB1). Seven mice were euthanized 
following surgery due to alterations in their general condition. 
 
Kindling 
Kindling of mice was initiated following a postsurgical recovery period of 2 weeks. During the 
experiments body weight varied between 30-50g (NMRI) and 20-35g (CamK-CB1 WT and KO). 
Mice were housed separately. 
The initial afterdischarge threshold (initial ADT) was determined for each animal using an ascending 
stair-step procedure with an initial current of 8 µA and an increase by 20% of the previous current 
every minute until afterdischarges were elicited (Pekcec et al. 2007). 
The amygdala was electrically stimulated once daily, five times per week with 700 µA (1 ms, 
monophasic square-wave pulses, 50 Hz for 1 s). The seizure severity was scored according to the 
Racine scale (Racine 1972): (1) Mouth and facial movements. (2) Head nodding. (3) Forelimb clonus. 
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(4) Rearing. (5) Rearing and falling. In addition to seizure severity, seizure duration and afterdischarge 
duration were recorded for each seizure event. The cumulative afterdischarge duration was calculated 
as the sum of all afterdischarge durations throughout the experiment. Following kindling acquisition, 
we determined the post-kindling afterdischarge threshold by the stepwise procedure (Pekcec et al. 
2007). 
 
Experimental details: kindling acquisition 
To minimize the impact of circadian variations, all experiments were performed within the same time 
of the day (1 pm to 6 pm). The initial afterdischarge threshold was determined twice on two 
consecutive days. Following determination of the first initial afterdischarge threshold without JZL-
treatment, the animals were distributed into a vehicle-treated and a JZL184-treated group with a 
comparable mean of the initial afterdischarge threshold and afterdischarge duration (Fig 2 A, B and 
Fig. 4 A, B). At the following day the second afterdischarge threshold was evaluated 60 min after drug 
or vehicle application. Due to the different genetic background NMRI mice received twelve and 
CamK-CB1 mice seven electrical stimulations until the majority of mice in the control group exhibited 
generalized stage (4) or (5) seizures (Fig.1, A). At stimulation day twelve, eleven out of twelve NMRI 
mice and at day seven nine out of ten CamK-CB1 WT mice in the control group exhibited generalized 
stage (4) or (5) seizures. We expected a misplacement of the electrode in the animals not exhibiting 
generalized seizure activity. Subsequent analysis revealed a correct localization in the right amygdala. 
Thus, data from these animals were included in further analyses.  
JZL184 or vehicle was administered with a volume of 10 ml/kg bodyweight in a dosage of 8 mg/kg 
once per day 60 minutes prior to the electrical stimulation. Following a washout phase of six days, we 
determined the post-kindling afterdischarge threshold.  
The experimental groups consisted of 12 animals per group for NMRI mice (vehicle-treated and 
JZL184-treated mice) and of 6-10 animals per group for CamK-CB1 mice (WT vehicle n=10, WT JZL 
n=7, KO vehicle n= 6 and KO JZL184 n=8). 
 
Experimental details: fully-kindled mice 
To minimize the impact of circadian variations, all experiments were performed within the same time 
period (8 am to 1 pm). Following determination of the initial afterdischarge threshold, NMRI mice 
(n=10) were electrically stimulated with 700 µA once daily, five times per week until they exhibited at 
least ten generalized stage (4) or (5) seizures (the number of stimulations to reach this kindling 
criterion ranged between 10 and 31) and were considered fully-kindled. Please note: known from 
several years of experience with different mouse strains, mice are kindled to reproducibly exhibit 
generalized seizures of stage (4) or (5); however, the highest seizure score (5) cannot always be 
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elicited in fully kindled animals. In contrast, rats reliably exhibit the highest seizure score once the 
fully kindled state is reached. 
Determination of afterdischarge thresholds was repeated in fully-kindled mice until thresholds proved 
to be stable allowing subsequent drug testing (Fig.1, B). Four days before the drug testing all mice 
received a re-stimulation with 700 µA. To evaluate the effects of the test compound three different 
dosages of JZL184 (4 mg/kg, 8 mg/kg and 16 mg/kg; i.p.) were injected in a volume of 10 ml/kg 
bodyweight 60 min prior to afterdischarge threshold determination. Each drug experiment was 
preceded by a vehicle control experiment two to three days before the previous drug administration to 
test whether control thresholds were in the same range as before. In addition to the afterdischarge 
threshold, the following seizure parameters were determined: generalized afterdischarge threshold, 
seizure severity, seizure duration, and afterdischarge duration. Each animal was used repeatedly with 
at least two days before the next vehicle control experiment, thus being its own control. The lowest 
dosage tested (4 mg/kg), decreased seizure duration and afterdischarge duration in a first experiment. 
Considering the lack of a dose-dependency of this effect, the experiment was repeated in the same 
group of animals. The effect was not reproducible. Please note that data of both experiments are 
combined in the results section.  
Two mice of the control group were identified as outliers (Grubb’s test) and excluded from further 
analysis. 
 
Treatment with the MAGL-inhibitor JZL184 
JZL184 [4 – nitrophenyl – 4 - [bis (1,3 – benzodioxol – 5 - yl) (hydroxy)methyl] piperidine – 1 - 
carboxylate] is a potent, highly selective and irreversible inhibitor of MAGL, which induces a rapid 
and long lasting up-to eight-fold elevation of 2-AG concentrations in the brain. Thereby anandamide 
levels are not altered (Long et al. 2009). The dosage of 8 mg/kg and the pre-treatment time (60 min) of 
JZL184 administration were chosen based on previous studies reporting central nervous system effects 
(Long et al. 2009). JZL184 was dissolved in DMSO (Sigma-Aldrich, Taufkirchen, Germany), 
cremophor EL (Sigma-Aldrich, Taufkirchen, Germany) and saline in a ratio of 1:1:18. The test 
compound was injected intraperitoneal with a volume of 10 ml/kg bodyweight. Control experiments 
with administration of the vehicle solution (DMSO, cremophor EL, saline; 1:1:18) were performed in 
parallel. 
 
Tissue preparation 
One day after the last seizure during the kindling acquisition phase, or eight days after the last drug 
experiment, mice were deeply anesthetized with pentobarbital (narcoren® 400mg/kg i.p., Merial 
GmbH, Halbergmoos, Germany) and transcardially perfused with 4% paraformaldehyde in 0.1 M 
phosphate buffer (pH 7.4). The brains were removed from the skull and placed into 4% PFA. On the 
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following day the brains were transferred into 30% sucrose and were stored at 4°C until further 
processing. Coronal sections (40 µm, five series) were cut on a microtome (Frigomobil, Reichert-Jung; 
Heidelberg-Nußloch, Deutschland). The brain sections were stored at -80°C in a cryoprotectant 
solution (glycerol and 0.1 M phosphate buffer, pH 7.4, 1:1 in volume). 
One of the series was stained with thionin for verification of the electrode localization. 
 
Statistics 
We performed statistical analysis of group differences using GraphPad Prism (Version 5.04, 
GraphPad, San Diego, CA, USA). Inter-group differences in kindling acquisition were detected with 
the Mann Whitney U-test and the unpaired t-test, if necessary with Welch’s correction, and the 
Fisher’s exact test. Two-way ANOVA for repeated measurements (dependent factor: time, 
independent factor: treatment/genotype) was performed by Statistica, v5.0 (StatSoft (Europe) GmbH, 
Hamburg, Germany). Vehicle –control and drug experiments were compared by One-way ANOVA 
for repeated measures followed by Bonferroni’s multiple comparison test or Friedman test followed by 
Dunn’s multiple comparison test using GraphPad Prism (Version 5.04, GraphPad, San Diego, CA, 
USA). Outliers were detected using the Grubbs' test (http://graphpad.com/quickcalcs/Grubbs1.cfm). 
All data are given as mean values ± SEM, and p < 0.05 was considered significant. 
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Results 
JZL184 administration increased the afterdischarge threshold at the beginning of the kindling process 
Afterdischarge thresholds were determined at the beginning of the kindling process (under JZL184-
treatment) and again at the end of kindling after a washout time of six days. Treatment with JZL184 at 
the beginning of kindling significantly increased the afterdischarge threshold by 233% (p=0.0325; 
Fig.: 2A) in NMRI mice. Afterdischarge threshold termination at the end of kindling without JZL184 
administration revealed no longtime effect between the two groups (p=0.8939; Fig.: 2A). As expected, 
repeated electrical stimulations throughout the kindling process reduced the afterdischarge threshold in 
both groups of NMRI mice (NMRI vehicle p=0.0008 and JZL184 p=0.0027; Fig.: 2A). 
 
Chronic JZL184-treatment delayed kindling acquisition 
The progression of seizure severity over time was attenuated in JZL184-treated NMRI animals 
(treatment effect p=0.0066; time effect p<0.0001; Fig.: 2C). The mean number of stimuli to reach a 
generalized stage four seizure was increased in these mice when compared to vehicle-treated animals 
(mean number of stimuli: vehicle n=6.3 ± 0.9 and JZL184 n=9.7 ± 0.9; p=0.0156; data not shown). At 
the final electrical stimulation with JZL184 administration 92% of vehicle- and 42% of JZL184-
treated animals experienced generalized seizures (stage 4 or 5; p=0.0272; Fig.: 2E). The analysis of 
the afterdischarge duration throughout the kindling phase and of its cumulative duration revealed a 
significant reduction in the JZL184-treated group (afterdischarge duration: treatment effect p=0.0012; 
time effect p<0.0001; Fig.: 2D; cumulative duration p<0.0001; Fig.: 2F). 
 
JZL184 has no effects in fully-kindled mice 
The effect of JZL184 on the afterdischarge threshold determined at the beginning of kindling and the 
lack of a longtime effect after the washout time indicated a putative anticonvulsant effect. Thus, we 
decided to evaluate the anticonvulsive potency of JZL184 in fully-kindled mice. None of the three 
different dosages tested (4, 8 and 16 mg/kg), affected the generalized afterdischarge threshold (GST) 
and associated parameters at threshold stimulation (seizure severity and seizure duration) in 
comparison to the preceding vehicle control experiment (Fig.: 3A-C). However, there was a trend that 
the afterdischarge duration recorded at the GST stimulation was slightly reduced. This effect, 
however, failed to reach significance following administration of 8 mg/kg JZL184 when compared to 
the respective vehicle experiment (p=0.0508; Fig.: 3C).  
The duration of behavioral and electrographic seizure activity was significantly decreased in response 
to 4 mg/kg JZL184 when compared to control mice. However, this result was not reproducible in a 
second experiment. Please note that data from the 4 mg/kg experiment show means calculated from 
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the two repetitive experiments. In summary, the overall effects of JZL184 are modest at most in fully-
kindled mice. 
 
Chronic JZL184-treatment has no effect in CamK-CB1 KO mice 
To address the CB1R dependency of JZL184 treatment, we evaluated the impact of JZL184 in CamK-
CB1 KO mice. As already reported previously (von Rüden et al. 2014), initial afterdischarge 
thresholds were reduced in CamK-CB1 KO when compared to littermate controls (p=0.0021). This 
genotype effect proved to be treatment independent (p=0.3018, 2-way ANOVA) and JZL184-
treatment did not affect initial afterdischarge thresholds in CamK-CB1 WT (p=0.1824) nor in KO-
mice (p=0.5725; Fig.: 4A). Repeated electrical stimulations throughout the kindling process reduced 
the afterdischarge threshold in CamK-CB1 WT vehicle 0.0325; Fig.: 4A). 
When CamK-CB1 WT mice were treated with the MAGL-inhibitor JZL184 at a dosage of 8 mg/kg, 
the treatment effects were the same as observed in NMRI mice. The progression of the seizure severity 
over time was attenuated in JZL184-treated CamK-CB1 WT (treatment effect p=0.002; time effect 
p<0.001; Fig.: 4C). At the final electrical stimulation 90% of vehicle- and only 29% of JZL184-
treated CamK-CB1 WT mice experienced generalized seizures (stage 4 or 5; p=0.0345; Fig.: 4E). In 
addition, the analysis of the afterdischarge duration throughout the kindling phase and of its 
cumulative duration revealed a significant reduction in the JZL184-treated CamK-CB1 WT 
(afterdischarge duration: treatment effect p=0.0002; time effect p<0.0001; Fig.: 4D; cumulative 
afterdischarge duration p=0.001; Fig.: 4F). In comparison, afterdischarge threshold and associated 
seizure parameters over time were comparable in JZL184-treated and vehicle-treated CamK-CB1 KO 
mice (afterdischarge threshold p= 0.5725; Fig.: 4A; seizure severity: treatment effect p=0.3107; time 
effect p<0.0001 Fig.: 4C; afterdischarge duration: treatment effect p=0.2334; time effect p=0.0733 
Fig.: 4D; cumulative discharge duration p=0.3269 Fig.: 4F) and all CamK-CB1 KO mice exhibited 
generalized seizures at the final electrical stimulation (seizure stage 4 or 5; Fig.: 4E). 
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Discussion 
Elevated 2-AG levels delay the development of generalized epileptic seizures 
In the present study, we demonstrate that JZL184 treatment increases seizure thresholds in naïve 
NMRI mice and delays the development of generalized epileptic seizures in the kindling model. 
JZL184 treatment strongly increases the concentration of 2-AG in the brain by a selective and 
effective block of the catabolizing enzyme MAGL (Long et al. 2009; Schlosburg et al. 2010; Wiskerke 
et al. 2012). Although we did not measure brain 2-AG levels in our experiment, the observed effects 
confirm that the dosage used was in the efficacious range. Our findings suggest that the indirect CB1R 
agonist JZL184 can exert protective effects that contributed to the delay of kindling progression and 
consequently lead to shorter duration of behavioral and electrographic seizure activity. This can be 
explained by reduced neurotransmitter release mediated by endocannabinoid signaling. Guggenhuber 
and colleagues (2010) overexpressed CB1Rs in hippocampal pyramidal and mossy cells and 
demonstrated a protective effect against seizures. In addition, it is known that CB1Rs on glutamatergic 
neurons can mediate a protection against excitotoxic seizures (Monory et al. 2006; Ruehle et al. 2013; 
von Rüden et al. 2014) and that endocannabinoid signaling during excessive excitation has stronger 
effects on hippocampal principal neurons than on GABAergic interneurons (von Rüden et al. 2014). 
Thus, we expect that during seizure activity the increased 2-AG levels predominantly activate CB1R 
on principal neurons and therefore suppress glutamate release. This may represent the key mechanism 
to control neuronal excitability during seizure activity.  
The indirect activation of CB1Rs offers a clear benefit compared with direct CB1R agonism, namely 
event-specific effects based on inhibition of the endocannabinoid degrading enzyme. The major site of 
action of JZL184 are those synapses with enhanced signaling and excessive postsynaptic on-demand 
production of 2-AG along with high presynaptic concentration of MAGL. MAGL expression reaches 
high levels in the principle cell layers of the hippocampal formation (Dinh et al. 2002; Uchigashima et 
al. 2011). Inhibition of MAGL in these neurons leads to enhanced CB1R activation and consequently 
to decreased neurotransmitter release. This might render an explanation for the delayed kindling 
progression in our model. A practical implication of this treatment strategy might be the event-specific 
elevation of 2-AG by the application of indirect agonists like JZL184. The goal is to increase the 
negative feedback loop mediated by endocannabinoids and thereby, prevent or at least slow down the 
generation of a hyperexcitable state. 
Accordingly, our findings are supported by recent in vitro studies. These studies show that 2-AG 
reduces excitatory post synaptic currents (EPSCs) in hippocampal slices from mice with temporal lobe 
epilepsy (Bhaskaran and Smith 2010), that enhanced 2-AG levels ameliorate kainate-induced 
epileptiform bursting in the CA1, and that 2-AG acting via CB1Rs blocks refractory status epilepticus 
in a dose-dependent manner (Deshpande et al. 2007; Fezza et al. 2014). These findings confirm an 
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effective inhibitory role of the endocannabinoid 2-AG in vitro. For future perspectives it would be of 
great interest to analyze local and regional system excitability in hippocampal brain slices of kindled 
treated and non-treated mice e.g. by electrophysiological methods to confirm treatment associated 
physiological changes on the cellular and network level. 
To our knowledge the only available in vivo study reports an increased seizure frequency and duration 
of spontaneous seizures in response to chronic JZL184 treatment in the pilocarpine model of temporal 
lobe epilepsy (Ma et al. 2014). In this study, a much higher JZL184 dosage was used (20 mg/kg twice 
daily versus 8 mg/kg once daily). One has to consider, that CB1R agonists often exert dose-dependent 
bimodal effects (Moreira et al. 2012). It might be possible that the increase in seizure frequency and 
seizure duration is related to the relatively high dosage and that low dosages, as we used, might 
promote protective effects. A plausible explanation might be the development of tolerance mediated 
by extensive down-regulation and desensitization of CB1Rs following chronic cannabinoid 
administration (Schlosburg et al. 2010; Lazenka et al. 2013).  
Evidence exists that 2-AG is the main endocannabinoid in the central nervous system (Katona et al. 
2006; Yoshida et al. 2006; Gao et al. 2010; Tanimura et al. 2010). Our data from this study and a 
previous study (Wendt et al. 2011) suggest that 2-AG might be the more effective endocannabinoid 
mediating protection from electrically induced seizures. Here, we confirm that 2-AG indeed promotes 
a delay in kindling progression along with decreased electrographic and behavioral seizure duration. 
This finding suggests that 2-AG signaling dominate anandamide signaling in the process of seizure 
progression. An explanation could be that in contrast to anandamide, 2-AG acts as a full agonist on 
CB1Rs and that therefore the activation of CB1Rs is more effective (Sugiura et al. 1999; Sugiura et al. 
2000; Sugiura et al. 2006). 
 
Elevated 2-AG levels have no anticonvulsive effects 
Based on our findings that JZL treatment delayed kindling acquisition, we wanted to exclude an 
anticonvulsive effect of JZL184 treatment in fully-kindled mice. In line with our idea, that activation 
of the endocannabinoid system might be a strategy to prevent epilepsy, JZL184 did not exert any 
robust but rather modest effects in this experiment. In line with these data, modulation of the 
endocannabinoid system with the direct CB1R agonist WIN55.212-2 and with the indirect CB1R 
agonist URB597 also lack a robust effect on seizure thresholds in kindled mice (Wendt et al. 2011). 
Altogether, our data argue against an acute anticonvulsive effect of JZL184 in the kindling model of 
temporal lobe epilepsy. With these findings, we were able to rule out that a mere anticonvulsant effect 
renders a bias, when testing the compound during kindling acquisition. This is one of the main effects, 
which might have biased previous studies in which anti-kindling effects of known antiepileptic drugs 
did not translate into clinical effects. 
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Inhibition of MAGL mediates cannabinoid 1-receptor dependent effects 
In a previous study, we characterized conditional CamK-CB1 mice, which lack CB1R in principal 
neurons of the forebrain, in the kindling model of temporal lobe epilepsy (von Rüden et al. 2014). 
These mice are more susceptible to seizures and have shorter seizure duration when compared to wild 
type controls, whereas the genotype has no impact on seizure progression. As expected, JZL184 
treatment in CamK-CB1 WT mice revealed the same effects as in JZL184-treated NMRI mice. In 
contrast, all analyzed parameters in vehicle- and JZL184-treated CamK-CB1 KO were comparable. 
Based on these findings we conclude that the effects of the MAGL-inhibitor JZL184 on kindling 
acquisition are predominantly CB1R mediated. 
However, one has to consider that 2-AG may act as GABAA-receptor agonist at low concentrations of 
GABA (Sigel et al. 2011). An interaction of cannabinoidergic and GABAergic systems during 
ictogenesis may be involved in the anticonvulsant action of endocannabinoids (Naderi et al. 2011), 
adding another level of complexity to endocannabinoid signaling in the central nervous system. 
However, we are able to exclude a relevant direct interaction, because we did not observe any effects 
of JZL184 in CamK-CB1 KO mice. If GABAA-receptors would be involved in JZL184 efficacy, then 
we should have seen a difference between treated and non-treated CamK-CB1 KO mice. 
 
Conclusion 
The aim of this study has been to evaluate whether pharmacological inhibition of MAGL by JZL184 
affects the development and progression of epileptic seizures in the kindling mouse model of temporal 
lobe epilepsy and to prove that JZL184-mediated effects are CB1R dependent. Our data demonstrate 
that indirect CB1R agonism can interfere with the development of generalized epileptic seizures in the 
kindling model, but has no anticonvulsive effects. Furthermore, we confirmed that the effects of 
JZL184 on kindling progression are CB1R mediated. 
These findings might imply that the endocannabinoid 2-AG may be a promising target for an anti-
epileptogenic approach. However, future studies in animal models with spontaneous recurrent seizures 
(e.g. in a post-status-epilepticus model) are necessary to confirm our hypothesis. 
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Figures 
Figure 1: 
 
Experimental design for (A) experiments analyzing kindling progression under JZL184- 
treatment and for (B) experiments in fully-kindled mice. (A) JZL184 was administered during the 
kindling stimulation phase. Animals were kindled until the majority of mice in the control group 
exhibited generalized seizures. Following the kindling procedure five days after the last 
JZL184/vehicle injection the post-kindling afterdischarge threshold was determined.  
(B) Animals were kindled until they exhibited at least 10 generalized stage (4) or (5) seizures and 
deterrmined to be fully-kindled. Fully-kindled mice were then repeatedly used for drug testing with 
administration of vehicle or JZL184 before threshold determination. Each drug experiment was 
preceded by a vehicle control experiment in the same animal. 
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Figure 2: 
 
Impact of JZL184 (8 mg/kg) on kindling progression in NMRI mice. (A) Initial afterdischarge 
thresholds pre-kindling without JZL184 treatment proved to be comparable in both groups, whereas 
JZL184 treatment at the beginning of the kindling process increased afterdischarge thresholds when 
compared to the control group. Kindling reduced the afterdischarge threshold in both groups. (B) 
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Initial afterdischarge duration pre-kindling in naïve mice proved to be comparable in both groups. (C) 
Seizure severity (SS) and (D) afterdischarge duration (ADD) are depicted for each day of stimulation. 
(E) The percentage of JZL184-treated animals with generalized seizures as well as (F) the cumulative 
discharge duration of JZL184-treated mice was significantly reduced when compared to vehicle-
treated animals. – JZL184: no drug pretreatment; + JZL-184: with drug pretreatment. All data are 
given as mean ± SEM, n.s.: no significant difference, * Significant difference p < 0.05, analyzed by 
two-way ANOVA for repeated measurement, Fisher’s exact test, unpaired student’s t-test, paired t-
test, and Mann Whitney test. Vehicle n = 12 and JZL184 n = 12. 
 
Figure 3: 
 
Impact of JZL184 in fully-kindled NMRI mice. (A) Generalized afterdischarge thresholds (GST), 
(B) seizure duration (SD) and (C) afterdischarge duration (ADD) recorded at threshold stimulation. 
There is a trend that JZL184 in a dosage of 8 mg/kg slightly reduced the afterdischarge duration when 
compared to the respective control experiment. All data are given as mean ± SEM, analyzed by one-
way ANOVA for repeated measures followed by Bonferroni’s multiple comparison test or Friedman 
test followed by Dunn’s multiple comparison test. Vehicle/JZL184 n = 9 (8 mg/kg experiment 
vehicle/JZL184 n=9). 
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Figure 4: 
 
Impact of JZL184 (8 mg/kg) on kindling progression in CamK-CB1 mice. (A) 	   Initial 
afterdischarge thresholds pre-kindling in non-treated mice proved to be comparable in both groups. 
Regardless of the treatment status (vehicle or JZL184) initial afterdischarge thresholds proved to be 
lower in CamK-CB1 KO mice when compared to respective controls. The kindling induced 
characteristic reduction of the afterdischarge threshold was only noticed in vehicle-treated CamK-CB1 
WT mice. (B) Initial afterdischarge duration pre-kindling in naïve mice proved to be comparable in 
both groups. (C) Seizure severity (SS) and (D) afterdischarge duration (ADD) are depicted for each 
day of stimulation. (E) The percentage of JZL184-treated CamK-CB1 WT mice with generalized 
seizures is significantly reduced when compared to vehicle-treated WT animals, whereas all CamK-
CB1 KO mice experienced generalized seizures. (F) The cumulative discharge duration of JZL184-
treated CamK-CB1 WT is reduced when compared to vehicle-treated WT animals, whereas treatment 
has no effects in CamK-CB1 KO mice. – JZL184: no drug pretreatment; + JZL-184: with drug 
pretreatment. All data are given as mean ± SEM, n.s.: no significant difference, * Significant 
difference p < 0.05, analyzed by two-way ANOVA for repeated measurement, Fisher’s exact test, 
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unpaired student’s t-test, paired t test and Mann Whitney test. CamK-CB1 WT: vehicle n = 10 and 
JZL184 n = 7; CamK-CB1 KO: vehicle n = 6 and JZL184 n = 8.
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DISCUSSION AND FUTURE PROSPECTS 
Activation of the endocannabinoid system can effectively modulate synaptic signal transmission 
(Katona and Freund 2008). Its inhibitory feedback mechanisms particularly protect against excessive 
presynaptic activity. Moreover, it has been described that activation of CB1Rs may affect neuronal 
plasticity. This includes the formation and fate of newly generated neurons in the dentate gyrus 
(Gordon and Devinsky 2001; Lutz 2004; Grant and Cahn 2005). The endocannabinoid anandamide 
can also activate TRPV1 channels (Smart et al. 2000), which leads to the increased release of 
glutamate (Peters et al. 2010). Therefore, not only targeting of the endocannabinoid system but also of 
the endovanilloid system is intensively discussed as a possible therapeutic strategy that could affect 
the formation of a hyperexcitable epileptic network, seizure thresholds and ictogenesis.  
In the present thesis we analyzed whether pharmacological and genetic modulation of the 
endocannabinoid and endovanilloid systems may affect epileptogenesis and ictogenesis in the kindling 
model of TLE. 
Most importantly, we have shown that the endocannabinoid, but not endovanilloid, signaling affects 
the termination of seizure activity dependent on the neuronal subpopulation. Moreover, we 
demonstrated that indirect CB1R agonism interferes with the development of a hyperexcitable 
network, but has only negligible anticonvulsant effects.  
Thus, the data argue that the endocannabinoid system plays an active role in seizure termination and is 
involved in the formation of a hyperexcitable neuronal network. These aspects are discussed in detail 
in the two research articles. Here I will discuss more general aspects with the focus on the hypothesis 
that the endocannabinoid system may be a promising target for the prevention and treatment of 
epilepsy. 
 
1. Pro- or anticonvulsant effects of CB1R modulation 
Among experts there is significant interest in the idea that cannabinoid agonists, as they are found in 
the marijuana plant Cannabis sativa, could have anticonvulsant properties. In the case of epilepsy, a 
handful of clinical trials and case reports support the anticonvulsant efficacy of cannabinoids (Cunha 
et al. 1980; Ng et al. 1990; Maa and Figi 2014). However, there are also conflicting reports arguing for 
no efficacy or even for proconvulsant effects (Gordon and Devinsky 2001; Schneir and Baumbacher 
2012). In conclusion, direct scientific data supporting the pro- or anticonvulsant potential is still 
missing. Recent insights come from basic science experiments which convincingly show that the 
endocannabinoid system has a central role in the regulation of neuronal excitability. CB1R agonists 
and antagonists have been tested in various in vitro and in vivo models of epilepsy, which also show 
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conflicting results. Cannabinoid agonists predominantly are anticonvulsant (Wallace et al. 2003; 
Bhaskaran and Smith 2010a; Wendt et al. 2011), whereas cannabinoid antagonists have proconvulsant 
effects (Wallace et al. 2002; Vinogradova et al. 2011; Arslan et al. 2013). The anticonvulsant property 
of endocannabinoids is mediated by excitatory glutamatergic neurons, whereas the proconvulsant 
activity depends on activation of inhibitory GABAergic neurons, leading to a decreased release of 
GABA, and accordingly to increased seizure susceptibility (Monory et al. 2006). 
However, it becomes more complex when looking at different animal models representing different 
types of epilepsy. Cannabinoid agonists have anticonvulsant properties in the rat pilocarpine model of 
epilepsy (Wallace et al. 2003; Falenski et al. 2007), in the PTZ-induced seizure model (Shafaroodi et 
al. 2004; Gholizadeh et al. 2007; Naderi et al. 2011) and in the penicillin-induced epilepsy model 
(Kozan et al. 2009; Cakil et al. 2011; Arslan et al. 2013). All these models are acute models of TLE 
induced by chronical enhancement of neuronal excitation. In this situation the activation of CB1Rs by 
agonists at excitatory synapses decreases glutamate release and is thereby protective (see Figure 7). 
On the contrary, CB1Rs on GABAergic interneurons have no impact in this context (Marsicano et al. 
2003; Monory et al. 2006). However, it would not be accurate to argue that CB1Rs on GABAergic 
neurons do not play a role at all. The present paper analyzed the modulation of the endocannabinoid 
system in the kindling model of TLE, another chronic epilepsy model. We were able to show, that 
CB1R deletion on GABAergic neurons of the forebrain results in shorter seizure duration and causes a 
decrease in motor and electrographic seizure durations after completing the kindling process. These 
results provide evidence that GABAergic interneurons play a role in the CB1R dependent control of 
electrically-induced behavioral seizures by the endocannabinoid system, but are undermined by 
glutamatergic signaling in the net-outcome during seizure activity. However, once the hyperexcitable 
neuronal network has developed, GABAergic signaling might be responsible for long-lasting 
protective effects, as indicated by decreased seizure duration in fully-kindled mice. 
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Figure 7. 
 
The dichotomous role of CB1R blockade and activation on neuronal excitability dependent on the 
neuronal subpopulation. As indicated on the left, CB1R blockade on glutamatergic neurons is 
proconvulsant, whereas blockade on GABAergic neurons is anticonvulsant. On the other hand, 
activation of CB1Rs on glutamatergic neurons is anticonvulsant, whereas activation on GABAergic 
neurons is proconvulsant. This scheme demonstrates that the endocannabinoid system has to be tightly 
regulated to ensure and maintain synaptic transmission in an optimal physiological range. Modified 
from (Lutz and Monory 2008). 
In animal models of epilepsy which are induced by disinhibition, the opposite is seen. In these models 
cannabinoid antagonists may have anticonvulsant properties. At first this idea seems to be intuitively 
wrong, as it is suggested that endocannabinoids decrease neuronal excitability (Marsicano et al. 2003). 
Considering that endocannabinoids act on both GABAergic and glutamatergic signal transduction 
(Chevaleyre et al. 2006), the explanation is obvious that enhanced inhibition may compensate an 
imbalance between stimulatory glutamate and inhibitory GABA, thus maintaining synaptic 
transmission in a physiological range. This might be explained by the dichotomous role of 
cannabinoid signaling at different neuronal subpopulations in the hippocampus (see Figure 7).  
In the epilepsy model of febrile seizures, long-term alterations in the GABAergic system lead to 
increased excitability of neurons (Chen et al. 1999) and thereby to uncontrolled neuronal firing. In this 
situation the endocannabinoid system regulates GABAergic but not glutamatergic signal transduction 
(Chen et al. 2007). Here, a blockade of CB1Rs by antagonists prevents increased inhibition and 
thereby elevates seizure thresholds.  
Taken together, these examples show that targeting of the endocannabinoid system may be a strategy 
for the development of drugs with a broad range of effects. However, one has to thoroughly analyze 
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the etiology of the epilepsy and the associated pathological neuronal alterations. This may help to 
identify whether CB1R agonists or antagonists will promote anti- or proconvulsant action.  
2. Pro- or antiepileptogenic effects of CB1R modulation 
In the paragraph above I highlighted the therapeutic potential of modulating the endocannabinoid 
system and its impact on epileptiform activity. In addition, there is evidence that endocannabinoids 
may act as antiepileptogenic agents. This aspect is of particular interest because until now, only 
symptomatic treatment is available and with the existing drugs, cure cannot be obtained. 
There are only a limited number of studies which address the hypothesis that the endocannabinoid 
system may be involved in the process of epileptogenesis (Echegoyen et al. 2009; Bhaskaran and 
Smith 2010a; Dudek et al. 2010; van Rijn et al. 2011; Wendt et al. 2011; von Rüden et al. 2014). 
Moreover, these studies revealed inconsistent findings. In a model of post-traumatic brain injury a 
single application of rimonabant, administered right after the injury, disrupted the process of 
epileptogenesis (Echegoyen et al. 2009). However, a second study in a different epilepsy model failed 
to show an antiepileptogenic efficacy of rimonabant (Dudek et al. 2010). Moreover, and in apparent 
contrast, van Riijn et al. (2011) chronically administered the CB1R antagonist and demonstrated a 
proepileptogenic effect. Taken together, these inconsistent findings stress the need for detailed 
analysis of CB1Rs in epileptogenesis. A more elegant and selective tool to address this issue consists 
of conditional knockout mice, which lack CB1Rs in specific neuronal subpopulation. Monory and 
colleagues (2006) were able to demonstrate that antiepileptogenic effects of CB1Rs are mediated by 
glutamatergic rather than GABAergic neurons. We also used the tool of conditional mutagenesis and 
analyzed the functional consequences of CB1R loss in the kindling model of TLE. However, genetic 
loss of CB1Rs did not exert any impact on kindling progression in this model, arguing against a 
crucial role of CB1Rs during epileptogenesis (von Rüden et al. 2014). Nevertheless, when we 
modified the endocannabinoid system pharmacologically with direct and indirect CB1R agonists in the 
same model, we detected an impact of CB1R activation on the development of seizure progression 
(Wendt et al. 2011; von Rüden et al., unpublished data). Although available experimental data are 
controversial, our studies in the kindling model of TLE, a model with excellent predictive validity, 
indicate that CB1R activation has an antiepileptogenic potential. These findings stress the fact that the 
endocannabinoid system is involved in the generation of hyperexcitable neuronal network formation. 
Moreover, from a therapeutic point of view, indirect agonists, like the enzyme inhibitor JZL184, offer 
a clear benefit compared with direct CB1R activation. Based on on-demand activation of the 
endocannabinoid system, this pharmacological intervention is event-specific and the resulting CB1R 
activation is locally restricted to excessively activated synapses. 
Taken together our studies help to increase the understanding of the importance of the 
endocannabinoid system in epileptogenesis even if a final conclusion is not yet possible.  
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3. Monoacylglycerol (MAGL) is a promising target for the prevention of epilepsy 
Anandamide and 2-AG are the two primary ligands for CB1Rs in the central nervous system. 2-AG is 
thought to be the major endocannabinoid in the brain (Sugiura et al. 1995; Stella et al. 1997), which, in 
contrast to anandamide, acts as a full agonist on CB1Rs with high efficacy (Sugiura et al. 1999; 
Sugiura et al. 2000; Sugiura et al. 2006). Although the concentration of 2-AG is regulated by MAGL 
(Dinh et al. 2002), the data for a supporting role of MAGL in modulating the endocannabinoid system 
was initially questionable. The first experimental studies, which demonstrated potentiated 
endocannabinoid action at inhibitory (Makara et al. 2005; Szabo et al. 2006; Hashimotodani et al. 
2007) and excitatory (Hashimotodani et al. 2007) synapses by MAGL inhibition, were discredited 
because of nonspecific binding and low binding affinity of the test compounds.  
Recently, a new and very selective MAGL-inhibitor, JZL184, has been developed and characterized in 
vitro and in vivo (Long et al. 2009; Schlosburg et al. 2010; Wiskerke et al. 2012).  
The findings of a previous study of our lab (Wendt et al. 2011) and data from this study, where we 
characterized the auspicious compound JZL184 in vivo in the kindling paradigm, suggest that 2-AG 
has an antiepileptogenic effect whereas anandamide is ineffective. In contrast to our findings, there is 
one recent contradictory in vivo study that reports proepileptogenic effects of JZL184 (Ma et al. 2014).  
A possible explanation might be the different dosages that were used in the two studies, which might 
promote opposing effects. These characteristics of endocannabinoids are known as dose-dependent 
bimodal effects (Moreira et al. 2012) and have to be seriously considered when it comes to therapeutic 
application. 
Anandamide and 2-AG regulate neuronal activity in two different ways. 2-AG preferentially acts on 
GABAergic synapses, whereas anandamide selectively reduces glutamate release (Ameri et al. 1999). 
Therefore, blocking the 2-AG degrading enzyme MAGL by specific inhibitors elevates 2-AG levels. 
This may improve GABAergic inhibition, which might in the following prevent or at least delay the 
generation of a hyperexcitable neuronal network as we have demonstrated in the kindling model of 
TLE.  
Considering all these aspects, MAGL-inhibition could be a promising new target for the prevention of 
epilepsy.  
 
4. The endovanilloid system has no crucial role in temporal lobe epilepsy 
The endocannabinoid anandamide activates not only CB1Rs but also TRPV1 channels (Smart et al. 
2000) by facilitating the release of glutamate in an activity-dependent manner (Peters et al. 2010). It 
has been confirmed that TRPV1 modulates glutamatergic signaling in the rodent and in the human 
brain (Mori et al. 2012) and that TRPV1 protein expression is altered in the hippocampus of mice 
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(Bhaskaran and Smith 2010b) and human patients with TLE (Sun et al. 2013). Therefore, targeting the 
endovanilloid system is suggested as a promising strategy for the regulation of neuronal activity in 
epilepsies (Lutz 2004). Recently, the non-psychoactive component cannabidiol of Cannabis sativa has 
been discussed among epilepsy researchers and granted orphan drug status under the name 
Epidiolex™ for the treatment of Dravet Syndrome, a rare and severe syndrome of infantile-onset, 
genetic, drug-resistant epilepsy in children. However, the molecular mechanism of the antiepileptic 
effects has not been well defined yet, and likely includes multiple mechanisms. Cannabidiol is 
supposed to act on various targets in the central nervous system, including CB1Rs and CB2Rs, 5-
HT1a receptors, FAAH/anandamide transporter inhibition, NF-ĸB, PPARγ, and also TRPV1 (Bisogno 
et al. 2001; Russo et al. 2005; Thomas et al. 2007; O'Sullivan et al. 2009; Leweke et al. 2012), 
mediating neuroprotective, antioxidative and antiinflammatory effects. It is possible that the 
modulation of all these different targets supplement each other in promoting antiepileptic effects. 
Thus, cannabidiol might be one of the “dirty” but effective drugs. However, our findings argue that 
targeting TRPV1 alone is insufficient to suppress seizures or to prevent the generation of a 
hyperexcitable neuronal network, as we did not find any impact of genetic or pharmacological 
modulation on epileptogenesis or ictogenesis. This statement might be valid only in the case for TLE 
and cannot be transferred to other epilepsy models, e.g., genetic epilepsy models of Dravet Syndrome.  
 
5. Future directions 
5.1. Considerations for cannabinoid therapeutics 
Cannabinoids as adjunctive anticonvulsant therapies 
Three main facts argue for the endocannabinoid system as a future antiepileptic or anticonvulsant 
therapeutic target: (1) the endocannabinoid system is involved in the regulation of neuronal 
excitability (Wilson and Nicoll 2002; Freund et al. 2003; Zhu and Lovinger 2005; Hofmann et al. 
2006); (2) the endocannabinoid system is altered in epilepsy or epileptic seizures (Ludanyi et al. 2008; 
Magloczky et al. 2010; Romigi et al. 2010; Zurolo et al. 2010; Gesell et al. 2013; von Rüden et al. 
2014); and (3) genetic and pharmacological modulation of the endocannabinoid system alters seizure 
susceptibility or seizure activity (Wallace et al. 2003; Monory et al. 2006; Wendt et al. 2011; von 
Rüden et al. 2014). There is strong evidence from experimental studies that some CB1R agonists exert 
anticonvulsant effects and that these effects are predominantly mediated through the activation of 
CB1Rs (Wallace et al. 2001; Wallace et al. 2002; Kow et al. 2014; von Rüden et al. 2014). 
Surprisingly, the effects of the non-psychoactive plant-derived cannabinoid cannabidiol are not 
mediated through a CB1R-dependent mechanism (Hill et al. 2013; Devinsky et al. 2014). 
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Clinical reports of the medical use of marijuana with high-ratio cannabidiol:Δ9-THC for the treatment 
of epilepsy claimed efficacy, but double-blind randomized and controlled studies and the mechanism 
of action are still missing (Devinsky et al. 2014). Nevertheless, for some special types of epileptic 
syndromes, like intractable childhood epilepsy (e.g., Dravet Syndrome and Lennox-Gastaut 
Syndrome), cannabidiol may help to reduce seizure frequency up to seizure freedom (Porter and 
Jacobson 2013; Maa and Figi 2014). Very recently, a pharmaceutical company, GW Pharmaceuticals, 
got the "orphan drug" status for Epidiolex™, a drug containing cannabidiol for the treatment of Dravet 
Syndrome (GW Pharmaceuticals. GW Pharmaceuticals provides update on orphan program in 
childhood epilepsy for Epidiolex. November 14, 2013. http://www.gwpharm.com/GW 
Pharmaceuticals Provides Update on Orphan Program in Childhood Epilepsy for Epidiolex.aspx 
Accessed March 3, 2014). The first clinical treatment outcomes show promising results and 
demonstrate a therapeutic potential of cannabidiol in the treatment of epilepsy. 
A strategy to bring new agents into clinics is to test them as adjunctive therapy in clinical trials. This 
strategy also has clinical relevance because polypharmacy with more than one antiepileptic drug is 
often required in the treatment of intractable epilepsy (Deckers et al. 2000). Indeed, the possibility of 
cannabinoids in adjunctive therapy is under investigation in experimental models of epilepsy. The 
Luszczki lab analyzed the combination of low dose arachidonyl-2’-chloroethylamide (ACAE), a 
cannabinoid agonist, and several classic antiepileptic drugs (clonazepam, ethosuximide, phenobarbital, 
valproate, carbamazepine, oxcarbazepine, lamotrigine, phenytoin and topiramate) in two different 
epilepsy mouse models (Luszczki et al. 2006; Luszczki et al. 2010; Andres-Mach et al. 2012). They 
were able to demonstrate that co-administration with phenobarbital, ethosuximide and valproate 
enhanced the anticonvulsant potential of these drugs without having negative adverse effects in 
behavioral tests of motor performance and long-term memory (Luszczki et al. 2006; Andres-Mach et 
al. 2012). However, the observed pharmacological effects were additive and increased the 
bioavailability of valproate and ethosuximide in the brain, whereas the free plasma and total brain 
concentration of phenobarbital was unaltered (Luszczki et al. 2006; Andres-Mach et al. 2012). In 
contrast, the anticonvulsant potential of the co-administration of ACEA and carbamazepine, 
oxcarbazepine, lamotrigine, phenytoin and topiramate was not affected (Luszczki et al. 2010). In a 
different study, Naderi et al. (2008) found a synergistic interaction of WIN55212-2, a direct 
cannabinoid agonist, and the benzodiazepine diazepam in a ratio of 1:3 (WIN55212-2:diazepam), 
whereas 1:1 and 3:1 ratios caused additive effects (Naderi et al. 2008). Surprisingly, the FAAH 
inhibitor URB597, the CB1R antagonist rimonabant and the endocannabinoid reuptake blocker 
AM404 in co-administration with diazepam revealed no interaction of the different compounds in 
anticonvulsion (Naderi et al. 2008). However, in this study total brain and free plasma levels have not 
been analyzed and therefore pharmacokinetic alterations cannot be excluded. It is also possible that 
CB1R mediated GABA-inhibition may counteract diazepam-mediated activation of GABA-receptors. 
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Alternatively, seizure dependent alterations of the endocannabinoid system may distract the balance of 
endocannabinoid signaling or even the effects caused by AEDs on neuronal inhibition and excitation, 
resulting in a modified net outcome of inhibition and excitation. Thus, the interaction of exogenous 
cannabinoids and AEDs is not that easy to explain. 
In summary, the findings from these research groups support the idea that administration of 
cannabinoid agonists may be promising for the treatment of intractable epilepsy when they are 
combined with AEDs that act on GABA receptors. In this context, it might be of interest to 
characterize the combination of the MAGL-inhibitor JZL184 with the classical AEDs and to analyze 
the impact on seizures to see if the action of these AEDs can be improved. 
 
5.2. Safety pharmacology of cannabinoid agents 
A widely held belief is that the acute toxicity of cannabinoids is low. Classical adverse effects in the 
medical use of marijuana are nausea, increased weakness, behavioral or mood changes, hallucination, 
dizziness, and fatigue (Koppel et al. 2014). These are more or less the same adverse effects that are 
observed with the classical AEDs and do not argue against clinical use. However, safety concerns like 
tolerance, withdrawal and dependence have to be seriously considered when cannabinoids are used for 
the treatment of epilepsy. 
Psychosis, dysphoria, and anxiety are adverse effects which occur at high concentrations of Δ9-THC 
(Koppel et al. 2014). Unfortunately, it is not reasonable to directly administer marijuana to epileptic 
patients because of its addictive and psychoactive side-effects, which are discussed in detail in the 
paragraphs below. 
 
Psychoactive side-effects 
The plant Cannabis sativa contains multiple components of which up to 60 are known to be active 
cannabinoids (Pertwee 2006). Its primary psychoactive component is Δ9-THC, acting as a partial 
agonist at CB1Rs (Pertwee 2006). A high CB1R density is found in brain areas which are strongly 
involved in the modulation of mood and motivation (Tsou et al. 1997), being a first explanation for the 
psychoactive effects of marijuana. Depending on the dose, on the cannabis strain and on the 
consumption frequency, the following psychoactive effects are described by users: mild euphoria, 
relaxation, sedation, loss of concentration but also enhanced sensory input, anxiety, paranoia, 
disorientation, and psychosis (Green et al. 2003). Moreover, the use of cannabis is associated with a 
higher risk of depression, schizophrenia and suicide (Serra and Fratta 2007; Foti et al. 2010; 
Nussbaum et al. 2011). Furthermore, the development of psychiatric complications is increased in 
adolescents with an early onset of cannabis consumption (Cuenca-Royo et al. 2013). 
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The composition of different phytocannabinoids determines the grade of psychotic effects. Plant 
strains with high rates of cannabidiol and low rates of Δ9-THC cause less severe psychotic symptoms 
(Schubart et al. 2011). Therefore, cannabidiol is one of the most promising phytocannabinoids for 
therapeutical use because it lacks psychoactive effects.  
However, when applied in the formulation of medical marijuana, great caution is needed. Medical 
cannabis contains hundreds of different cannabinoids and there is no quality control of the diverse 
cannabinoid ratios, resulting in a non-standardized medical mixture. In particular, patients with 
cardiovascular diseases, mental disorders or adolescents should use medical marijuana with utmost 
caution (Borgelt et al. 2013). This potential risk has to be kept in mind especially when talking about 
the use of medical marijuana for the treatment of Dravet Syndrome or Lennox Gastaut Syndrome of 
children because children have per se a higher risk of psychiatric side effects. 
Human and animal studies provide evidence that not only phytocannabinoids but also synthetic 
cannabinoids constitute the risk of psychotic side-effects (Roohbakhsh et al. 2007; Ugur et al. 2008; 
Moreira and Crippa 2009; Moreira and Wotjak 2010; Moreira et al. 2012). However, a synthetic 
cannabinoid which completely lacks psychoactive side-effects has not been developed so far. But the 
search for a safe and efficacious compound continues and new synthetic cannabinoids with better 
pharmacodynamics and pharmacokinetics as well as fewest possible side-effects are constantly 
developed.  
 
Dependence and withdrawal 
For a long time cannabis was not considered to be a drug of abuse or dependence. It was considered as 
a harmless drug. Dependence is defined by the National Institute on Drug Abuse as “a state in which 
an organism functions normally only in the presence of a drug” and is “manifested as a physical 
disturbance when the drug is removed (withdrawal).” 
Today, the abuse potential of cannabis is recognized and up to 10% of regular users are defined as 
substance dependent (Iversen 2003). Increasing evidence from animal and clinical studies support the 
claim that dependence and withdrawal exists and specific withdrawal symptoms like anxiety, 
irritability, depressed mood, restlessness, sleep disturbances, gastrointestinal symptoms, and decreased 
appetite have been identified (Iversen 2003; Budney et al. 2004). Studies in rodents demonstrate that 
they self-administer the cannabinoid agonist WIN55212 (Ledent et al. 1999) and severe withdrawal 
symptoms can be provoked by administration of the CB1R antagonist rimonabant after chronic 
administration of cannabinoid agonists (Aceto et al. 1998; Aceto et al. 2001; Moranta et al. 2009). 
Moreover, the phenomenon of rebound hyperexcitability during the withdrawal phase is a 
consequence that has to be considered in the context of epilepsy. In the pilocarpine model of epilepsy 
the seizure frequency and seizure duration was increased when rimonabant was administered 
following chronic administration of WIN55212 (Wallace et al. 2003). These findings clearly prove 
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that dependence and withdrawal exist. However, dependence, withdrawal and rebound 
hyperexcitability should not exclude cannabinoids as anticonvulsants. It is more a question of how to 
handle these difficulties. In addition, many of the current AEDs used in clinical practice also cause the 
above mentioned phenomena. Moreover, it is state-of-the-art to gradually taper down medications over 
weeks rather than ending the application abruptly. Therefore, dependence and withdrawal have to be 
taken seriously but should not limit the use of cannabinoids as anticonvulsants in the therapy of 
epilepsy. 
 
5.3. Tolerance issues of cannabinoid agents 
Another important issue that one has to bear in mind is the development of tolerance when considering 
cannabinoids for therapeutic use.  
By now, it is well known that the pharmacological effects of Δ9-THC or synthetic cannabinoid 
agonists experience tolerance as well as cross-tolerance to their classic effects, like ataxia, 
hypolocomotion, hypothermia, and analgesia following chronic administration (Wiley et al. 1993; Fan 
et al. 1994; Lamb et al. 2000). Tolerance or cross-tolerance occurs along with prolonged exposure of 
Δ9-THC or synthetic cannabinoid agonists simultaneously with CB1R desensitization via uncoupling 
of the G-protein signaling cascade and downstream effectors, as well as receptor downregulation via 
receptor internalization. The extent of CB1R desensitization and downregulation vary by brain region. 
For example, the hippocampus is a highly privileged region of rapid CB1R alterations (Sim-Selley 
2003; McKinney et al. 2008). This pattern is comparable in the human and rodent brains (Villares 
2007; Hirvonen et al. 2012).  
Experimental in vitro and in vivo studies in epilepsy research suggest a dose- and duration-dependent 
manner of tolerance development. In a hippocampal neuronal cell culture model, Blair and colleagues 
(2009) observed after prolonged exposure to WIN55212 CB1R downregulation along with 
proconvulsant activity. Early in vivo studies are in line with these findings showing, reduced Δ9-THC 
efficacy after multiple applications in electrically kindled rats (Fried and McIntyre 1973; Corcoran et 
al. 1978) and in gerbils with spontaneous seizures (Ten Ham et al. 1975). Although the aspect of 
tolerance may be the main hurdle for the use of cannabinoids for the treatment of epilepsy, newer 
studies did not investigate this issue any further. 
As mentioned above, indirect CB1R agonists offer the advantage of site-specific activity, with low 
CB1R activation elsewhere. The indirect acting CB1R agonist JZL184, which we used in our 
experiments, covers this advantage. However, it is known that chronic administration of high dosages 
of JZL184 (40 mg/kg) induces tolerance, CB1R desensitization, and alterations in synaptic plasticity 
as well as cross-tolerance to WIN55212 (Schlosburg et al. 2010). Recently, Kinsey and colleagues 
(Kinsey et al. 2013) demonstrated that tolerance and associated alterations as well as cross-tolerance 
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can be avoided by using low doses of JZL184, even when repeatedly administered. This is in line with 
our findings. Low doses (we used 8 mg/kg) repeatedly administered delayed kindling progression 
without losing efficacy or being proconvulsant at any time. Thus, we have not seen any evidence for 
tolerance development. However, we did not analyze CB1R density or cross-tolerance to other 
cannabinoid agonists. Nevertheless, our data in combination with those of the Kinsey lab indicate that 
partial inhibition of MAGL may be a potential targeting strategy for the treatment of epilepsy, which 
can avoid the development of tolerance as well as cannabinoid mimetic side effects. 
Collectively, it is very important to further analyze the molecular mechanisms underlying tolerance 
development to find strategies which overcome this serious problem. 
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CONCLUSION 
This thesis sought to determine if pharmacological and genetic modulation of the endocannabinoid 
and endovanilloid systems may have preventive antiepileptogenic properties in the kindling mouse 
model of TLE. 
We found that CB1Rs expressed in the forebrain increase or decrease seizure duration dependent on 
the neuronal subpopulation, but that cell-type-unspecific pharmacological blockade of CB1Rs 
prolongs seizures. These findings allow the conclusion that the endocannabinoid system is involved in 
seizure termination as an important endogenous mechanism and that endocannabinoid signaling in 
hippocampal glutamatergic principal neurons overrules endocannabinoid signaling in GABAergic 
interneurons during seizure activity. 
Furthermore, genetic and pharmacological modulation of the endovanilloid system had no impact on 
the generation of a hyperexcitable neuronal network or on ictogenesis, proposing that targeting 
TRPV1 alone is not a sufficient strategy to prevent epileptogenesis or suppress seizure activity in TLE. 
In addition, the investigation of the role of the indirect CB1R agonist JZL184 in the development of a 
hyperexcitable network and in ictogenesis shows that JZL184, by blocking MAGL, delays kindling 
acquisition but has no relevant effects in fully-kindled mice. Further, we were able to confirm that the 
effects of JZL184 on kindling progression are CB1R mediated. 
Altogether, these findings demonstrate that the endocannabinoid system can be considered as a target 
for decreasing seizure duration and supporting the endogenous mechanisms of seizure termination. 
Moreover, targeting MAGL may be a promising strategy for an antiepileptogenic approach. 
Respective strategies are of particular interest on the one hand for the management of long-lasting 
refractory status epilepticus and cluster seizures, and, on the other hand, for a prophylactic treatment to 
prevent the development of symptomatic epilepsies after an initial insult. 
This thesis helps to reveal new details of the role of the endocannabinoid and endovanilliod systems in 
ictogenesis and epileptogenesis, which may help to develop new options for the treatment and 
prevention of TLE. 
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